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ABSTRACT
Baiming Zou: Robust and Efficient Statistical Inference for Clustered
Observational Data in Comparative Effectiveness Research
(Under the direction of Professor Haibo Zhou)
Treatment allocations in observational studies are nonrandom and result in the
confounding problem and potentially biase treatment effect estimates. Propensity score
(PS) methods are commonly used in practice to address the confounding problem.
Among different PS methods, PS regression is frequently used in clinical research. Even
though the treatment effect estimate from the PS regression model is unbiased under
the strongly ignorable treatment assignment assumption, the default variance estimate
is biased. In the first topic of this dissertation, an improved variance estimator for the
treatment effect estimate is proposed.
Many observational data are clustered, for example, by physicians, and are there-
fore, not independent. A few PS methods consider correlated or clustered samples
using mixed effects models with a strong normality assumption on the cluster effects.
In the second part of this dissertation, a robust semi-nonparametric propensity score
(SNP-PS) regression model is proposed. We relax the normality assumption and model
the complex heterogeneity structure in treatment allocation process nonparametrically.
The proposed SNP-PS model is robust and provides unbiased treatment effect esti-
mates while parametric mixed effects PS models fail to do so when the cluster effects
are non-normally distributed. We establish the asymptotic result for the treatment
effect estimate and propose an unbiased variance estimator for it. Computationally, we
propose an adaptive quadrature integration EM (expectation-maximization) algorithm
to avoid potential large Monte Carlo errors of existing Monte Carlo EM algorithms.
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Many real world medical record data are not only clustered but also multilevel
clustered with millions of samples and hundreds of thousands of clusters. The SNP-PS
framework is in theory applicable to these large datasets. However, in practice, it is
computationally prohibited. In the third topic of this dissertation, we propose a flexible
mixed effects PS model (FM-PS) that is computationally efficient for large multilevel
clustered data. The FM-PS model relaxes a critical independence assumption that
the random effects are independent of the fixed effect covariates made in the standard
mixed effects PS (SM-PS) models. The FM-PS model provides an unbiased treatment
effect estimate regardless whether the independence assumption holds or not. Though
the treatment effect estimate from the SM-PS model is biased when the independence
assumption does not hold, it is unbiased and more efficient than the estimate from the
FM-PS model when the independence assumption holds. We propose a likelihood ratio
statistics for testing the independence assumption which allows us to choose between
the FM-PS and SM-PS models. A cluster bootstrapping procedure to estimate the
variance of treatment effect estimate is proposed. The FM-PS model is robust to
various model misspecifications as demonstrated by our extensive simulations.
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Chapter 1
Introduction
1.1 Medical Record Data
1.1.1 Features of Medical Record Data and Its Applications
Randomized controlled trial (RCT) is routinely used in clinical research for esti-
mating treatment efficacy in drug development and is considered as the gold standard
to establish causal effects of drugs. In randomized controlled trials, treatments are
randomly assigned by researchers. Proper randomization procedures guarantee that
there exists no systematic difference among subjects for their baseline features in dif-
ferent treatment groups. Therefore, valid treatment effects can be estimated easily by
comparing the outcomes from different treatment groups directly without the need to
adjust for any other covariates.
Even though RCTs are regarded as one of the best designs to evaluate efficacy of
drug therapies or other medical interventions, RCTs have their limitations (e.g. Kramer
and Shapiro 1984). First, RCTs are expensive to conduct and thus small sample sizes
are commonly observed in RCTs (Johnston et al. 2006). Second, experiments in RCTs
may have involved a specific group of people and conducted under certain situations
within a short time period. Third, the conduction of a randomized controlled trial
usually is time consuming (e.g. for recruiting enough participants). Fourth, RCT is not
always applicable due to ethical considerations. Fifth, some side effects of medications
may not be able to be fully detected in RCTs due to short time period, small sample
size, and/or limited participants. With all these limitations of RCTs, observational
data, including the medical record data, have been extensively used as alternatives for
the evaluation of therapy effectiveness or even drug efficacy.
Medical record data is a systematic collection of medical information for individual
patients. A medical record usually contains various information, including personal
and physical information like age, weight and blood pressure, family disease history,
treatment assignment, demographics, medical history, medication and allergies, im-
munization status, laboratory test results, radiology images, vital signs, and billing
information, etc for each patient. Rich information included in medical record data can
be used for various purposes including statistical reporting on quality improvement,
resource management and public health communicable disease surveillance, etc.
In recent years, medical record data have been increasingly used for comparative
effectiveness research (e.g. Cebul et al. 2011; Schneeweiss and Avorn 2005; Suissa
and Garbe 2007; Lau et al. 2011). The advantage of using medical record data for
treatment effect estimate is that it offers broader population spectrum than the tra-
ditional randomized controlled trials (RCTs) because often participating subjects are
highly heterogeneous in terms of their medical and social backgrounds. In addition,
in practical medical record data, the treatments are assigned based on patients’ clin-
ical needs. Therefore, treatment effects from medical record data more closely reflect
daily clinical practice than randomized controlled trials and provide clinically relevant
information that may not be provided by RCTs (Yang et al. 2010). Treatment effects
estimates using practical medical record data may supplement the evidence obtained
from randomized controlled trials. Furthermore, comparative effectiveness research us-
ing medical record data and conducted with well-established statistical methods can
improve causal inference of treatment effects (Berger et al. 2009). The retrospective
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analysis of medical record data can bridge the inferential gap between what is proved to
be effective for the selected groups of patients versus the complicated clinical decisions
required for individual patients (Stewart 2006). Large medical record database can
help to identify the rare adverse event for medications that was not able to be detected
in RCTs. Medical record data have become a valuable resource for comparative effec-
tiveness research that allows researchers to determine the inferiority, equivalence, or
superiority of various interventions when compared with each other (e.g. Mitka 2010).
However, there exist controversy and challenges on whether the medical record
data can provide reliable information on treatment effect estimate (e.g. Pocock and
Elbourne 2000; Ioannidis and Lau 2001). Some studies reveal reasonable results compa-
rable to that from randomized controlled trials. On the other hand, some comparisons
identify inconsistent results with RCTs. For example, statin therapy was found to de-
crease the overall mortality and myocardial infarction based on Weiner et al. (2008)
research. Weiner et al. (2008) used medical record data from the United Kingdom
General Practice Research Database (GPRD) which includes the compiled information
for over 8 million patients. These results were reasonably comparable to that from
other RCTs. But, in the same study, they found disparity between the results based on
GPRD database and that from RCTs about the effect of statin therapy for coronary
revascularization. Another example, prophylaxis is shown to reduce the occurrence of
venous thromboembolism among critically ill patients (The PROTECT Investigators
2011) in the randomized controlled trial. However, the trial findings extended to real
world patients have been inconclusive (Sharpe et al. 2002). While some studies found
that observational studies and RCTs are overall comparable and produced similar re-
sults (e.g. Benson and Hartz 2000; Concato et al. 2000), other research identified that
discrepancies beyond chance do occur and differences in estimating the magnitude of
treatment effect do often exist (e.g. Ioannidis et al. 2001).
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Even though one could attribute some of the inconsistent results between obser-
vational studies and randomized controlled trials to the lack of rigorous inclusion and
exclusion criteria, exposure definitions and outcomes identical to the RCT (Tannen et
al. 2008), the key difference between RCT and the real world medical record data is
that the treatment assignment in real world medical data is not random. In medical
record data, the treatment allocation of each patient is primarily made by physicians
according to the patient’s physical condition, disease severity, the physician’s preference
of a therapy, etc. Nonrandom treatment assignment of medical record data could result
in large differences in the baseline covariates between the treated and untreated groups.
The imbalanced baseline covariates distributions may twist the treatment effect, i.e. a
problem known as confounding.
Apart from its distinctive observational feature, another key feature of medical
record data is the clustering feature, for example, by physicians, clinics, hospitals, and
insurance agencies. The clustering feature of medical record data often reflects the
heterogeneity in patients’ health conditions, social economical status, and so on, which
not only plays important roles in treatment assignment decision but also affect the
disease outcomes. To obtain valid treatment effect estimate for clustered observational
data, it is critical to take into consideration of confounding and sample heterogeneity
features. The following two subsections review existing statistical methods for clustered
observational data.
1.1.2 Review of Confounding Adjustment Methods
The large and heterogeneous populations included in medical record datasets pro-
vide ideal resources to examine treatment effects and outcomes under real world condi-
tions over long periods. However, the bias induced by the confounding factors restricts
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medical records’ capacity to distinguish treatment effects from the effects of patient-
related, disease-related, and provider-related factors, etc. Ignoring or inappropriately
adjusting the confounding may result in biased treatment effect estimate and erroneous
conclusions. A large number of confounding adjustment methods have been proposed
in the literature to assess the treatment effects for non-randomized data which usu-
ally fall into the following categories: matching, stratification, instrumental variable,
multiple regression, and various versions of propensity score methods.
Matching
Matching is the simplest and most intuitive confounding adjustment method to
account for selection bias under non-randomized design (e.g. Rubin 1973; Wacholder
1992; Greenland et al. 1981; Miettinen 1968; Kupper et al. 1981; McKinlay 1977;
Rose and van der Laan 2009). The idea is similar to that of randomized trials in
making the confounding factors balanced as much as possible between treated and
untreated groups. Basically, matching procedure first identifies a set of confounding
covariates , i.e. the factors that are potentially related to both the dependent outcomes
and the independent variable of interest (i.e. the treatment assignment). For each
covariate in the set of identified confounding covariates, a subject in the treated group
is matched with another subject in the untreated group with (nearly) identical value of
the confounding covariate considered. Then, by doing this way, the subjects matched
will be almost balanced with respect of the confounding covariates between the treated
and untreated groups. In this sense, matching can be viewed as a manually created
RCT.
Matching is simple and straightforward to implement. In many cases, it provides
reasonable solutions to control confounding factors and reduce bias in treatment effect
estimates (Wunsch et al. 2006). Matching can also reach a balanced number of treated
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and untreated across the levels of the selected matching variables. This balance can
reduce the variance in the parameter estimates of interest and improves statistical
efficiency (Kupper et al. 1981; Rothman and Greenland 1998). However, intrinsic
limitations exist for matching which restrict its practical applications. In situations
where many confounding factors exist, matching can be difficult, and result in low
sample overlap. Matching with low sample overlap will cause inefficiency because those
unmatched subjects have to be thrown away without including in the analysis. More
importantly, how to select a “right” set of confounding variables is tricky but important.
Inappropriately selecting the covariates to match over will lead to overmatching issue.
Overmatching could severely lower the statistical analysis power and lead to a new bias
(Day et al. 1980).
Stratification
Stratification is another simple approach for confounding adjustment (Cochran
1968; Miettinen 1976). Similar to matching procedure, stratification procedure also
identifies a list of potential confounding variables first. It identifies two or more mu-
tually exclusive subgroups or strata within which the confounding variables are largely
constant. For each of the identified confounding covariates, a set of subgroups are
created such that the covariate is similar within each of the subgroup, for example
classifying age into decades, or weight into quartiles. Subgrouping will be subsequently
performed within each subgroup based on another remaining confounding factor from
the list. The subgrouping process continues till no more remaining confounding vari-
ables left in the list or there is no more subjects to be classified. Stratification process
usually generates a tree and the height of the tree and the number of nodes created
depending on the number of confounding covariates and the number of samples. The
order of nodes created from stratification depends on the order of confounding factors
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used in the subgrouping procedure. This means that different stratification order on the
confounding variables could lead to different treatment effect estimate. After subgroups
are created, stratify analysis is performed.
After the intervention effect is estimated within each stratum, a pooled estimate is
calculated across strata to generate the final overall estimate. Weighting is commonly
used for combining each stratum’s estimate to obtain the overall estimate (noted as
adjusted estimate). Mantel-Haenszel method (Mantel and Haenszel 1959) is the most
popular approach for this purpose. It uses a weighted average of the stratum-specific
estimates to obtain the overall estimate. The weights are inversely proportional to the
variances of the stratum-specific estimates, i.e. the more precise the estimates are, the
greater weights they get. Homogeneity of stratum-specific estimates can be tested via,
for example χ2 test. In this sense, stratification method is similar to the meta-analysis
where the goal is to combine treatment effect estimates from different studies.
The algorithm of stratification is simple to implement and robust without specific
assumptions for the distributions of confounding variables and no linear relationship
between the outcome and confounding factors is assumed (Cochran 1968). Results
based on stratification are clear and easy to interpret (Klungel et al. 2004). However,
several limitations exist for this method. First, the computational workload could be
intensive since the number of subgroups can increase exponentially with the increase
of the number of confounding covariates and the number of subjects. Second, grouping
based on continuous variables would be subjective where the original continuous con-
founder is replaced by a less accurate, categorical version. This may lead to residual
confounding if the strata is not fine enough (Becher 1992). As a result, stratification
usually is restricted to categorical variables. All these make stratification method less
practical for large datasets with a number of confounders, such as medical record data.
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Instrumental Variable
Instrumental variable (IV) method is another well-known confounding controlling
approach and has been widely used in economical research (e.g. Angrist and Krueger
2001; Heckman 1997; Miguel et al. 2004). It is later introduced into clinical research
(e.g. McClellan 1994; Permutt and Hebel 1989; Vansteelandt et al. 2011). Even though
it is mainly used for confounding adjustment purpose under observational design, it is
used for causal inference as well (Angrist et al. 1996). An instrumental variable is
an observed covariate that is associated with the independent variable of interest (e.g.
treatment assignment) but not with the random measurement error term. In other
words, the instrumental variable is associated with the independent variable of interest
but NOT associated with the outcome directly. That is the effect of an instrumental
variable on the dependent variable is indirectly through another independent variable.
IV approach can be demonstrated by the following regression model:
yi = β0 + β1xi + i (1.1)
A variable z is called an instrumental variable of the regressors x if z is uncorrelated
with the error term  but correlated with x. A simple example can demonstrate how
this scenario can happen. Suppose y has the following true linear relationship with x∗:
yi = β0 + β1x
∗
i + 
∗
i (1.2)
Suppose x is observed via x∗ with an error ξ such that xi = x∗i + ξi, where x
∗
i and ξi are
independent. Then the true regression equation (1.2) for regressor x∗ can be rewritten
by using its proxy x as equation (1.1) with i = 
∗
i − β1ξi. Therefore, regressor x is
correlated with the error term  since Cov(x, ) = Cov(x∗ + ξ, ∗ − β1ξ) = −β1var(ξ).
In the above regression equation (1.1), βˆ from OLS is biased and inconsistent.
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Suppose now we have another variable z which equals x∗. By the definition of IV, it is
easy to prove that z is an IV of x. Based on z, we can get the instrumental variable
estimator for β as:βˆIV = (z
′x)−1z
′
y. It can be shown that E(βˆIV ) = β, thus βˆIV is an
unbiased estimator of β.
In practice, the IV estimator is obtained via two-stage linear regression. That is,
for each confounding covariate x, identify the corresponding instrumental variable and
do the first stage linear regression for the confounding covariate as dependent variable
against the instrumental variable and obtain the prediction for x, i.e. xˆ. Substitute x
with xˆ in the original regression model and conduct the second stage linear regression
to obtain the parameter estimate.
The IV estimator is consistent and the procedure to obtain IV estimate is simple
and straightforward. Studies by Brookhart et al. (2006) show that the instrumental
variable method could substantially reduce the bias due to unobserved confounding.
However, there exist limitations for this method also. For example, the requirements
for IV are difficult to satisfy and test in practice, such as the independent assumption
on the instrumental variables with respect to the error term (Klungel et al. 2004).
Therefore, it is not an easy task to identify an instrumental variable. In practice, the
determination of an instrumental variable is subjective. Therefore, the generalization
of the findings from the IV method is questionable (Klungel et al. 2004). As such, the
validity of using IV for treatment effect estimate under non-randomized design remains
debatable.
Multiple Regression
Multiple regression can be used to adjust the effects of confounding factors directly.
Advantages of regression methods include allowing many confounding variables being
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included in the model and the possibility of incorporating quantitative continuous fac-
tors without categorization and the possibility of modeling trends in confounders mea-
sured on an ordinal scale. Multiple regression method is regarded as the gold standard
method for adjusting confounding factors since it would provide the best linear unbi-
ased estimates (BLUE) when the assumptions for the regression model hold. However,
such efficiency gains would be at the risk, for examples when the number of confounding
variables is not small (with respect to the number of samples) and the regression model
is incorrect (such as covariate functional form misspecified). Furthermore, in regression
analysis, limited overlapping of confounding covariates between treatment groups may
lead to multicollinearity.
Propensity Score
As an alternative for multiple regression method, propensity score (PS) method by
Rosenbaum and Rubin (1983) is often used in practice (e.g. Seeger et al. 2005; Huang
et al. 2005; Sturmer et al. 2006; Hong and Yu 2008; Wyse et al. 2008; Staff et al. 2008;
Lunt et al. 2009; Ye and Kaskutas 2009) to adjust for confounding factors and estimate
the treatment effect under non-randomized design via stratification, matching, inverse
probability weighting, or covariate adjustment.
A propensity score is defined as the conditional probability of a unit (e.g. person)
being assigned to a particular treatment in a study given a set of known covariates.
Let the binary variable trt refer the treatment assignment (with 1 for treated and 0 for
untreated) and x refer the vector of the covariates.
PS = Pr(trt = 1 | x)
In randomized controlled trial, this probability is known and independent of covariates
or the observed features x, i.e. trt ⊥ x or Pr(trt = 1 | x) is a constant (usually
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it is set as 0.5) regardless of x. In observational studies, the propensity of receiving
treatment is unknown but depends on x, i.e. the treatment allocation depends on other
covariates. Imbalance of propensity score indicates an imbalance in covariates between
the two comparison groups. The goal of propensity score analysis is to balance two
non-equivalent groups based on their propensity scores to reduce the selection bias in
the treatment effect estimate.
The validity of the PS method is built on the following two fundamental assump-
tions:
(y(1), y(0)) ⊥ trt|x (1.3)
0 < P (trt = 1|x) < 1. (1.4)
where y(1) and y(0) are the potential outcomes of a particular unit under the treated
and untreated, respectively. That is, y(1) and y(0) are the outcomes if the unit had
been assigned to the treated and untreated group, respectively. They are never ob-
served simultaneously in reality. Their relationship with the observed outcome y and
the treatment assignment trt can be expressed as y = trt ∗ y(1) + (1− trt) ∗ y(0). The
first condition (1.3) says that treatment assignment is independent of the potential out-
comes conditional on the observed baseline covariates. Rosenbaum and Rubin (1983)
had shown that conditional on the propensity score, the distribution of measured base-
line covariates is similar between the treated and untreated subjects. Thus, for a set of
subjects who have the same propensity scores, the distributions of the baseline covari-
ates will be the same between the treated and untreated groups. They demonstrated
that if treatment assignment is strongly ignorable(i.e. conditions (1.3) and (1.4) hold),
conditioning on the propensity score allows one to obtain unbiased estimates of the
treatment effects. This condition is also referred to as the no-unmeasured confounders
assumption,i.e., all confounding variables that affect the treatment assignment and the
11
outcome have been measured and included in x. Under this assumption it has been
shown that adjustment made with the propensity score is sufficient to remove the bias
due to the non-random treatment assignment in both large and small sample scenarios
(Rubin 1997).
In practice, the propensity score is unknown and commonly estimated via the logistic
regression model:
logit(Pr(trti = 1 | xi)) = β0 + xiβ (i = 1, · · · , n) (1.5)
where xi represents all the observed covariates other than the treatment assignment
trti (1 for treated and 0 for untreated) of subject i. Denote the parameter estimates of
β0 and β (i.e. maximum likelihood estimates (MLE)) as βˆ0 and βˆ. Then, PS can be
estimated as:
P̂Si = exp(βˆ0 + xiβˆ)/[1 + exp(βˆ0 + xiβˆ)]
A critical aspect of PS based method is to obtain valid PS estimation which often
involves model and variable selection (e.g. Brookhart et al. 2006). Even though
the prevailing propensity score estimation method is logistic regression, several other
propensity score estimation methods have been proposed such as boosting and bagging
(Lee et al. 2010; McCaffrey et al. 2004), random forests (Lee et al. 2010), neural
networks (Setoguchi et al. 2008), and regression tree or partitioning methods (Lee et
al. 2010; Setoguchi et al. 2008).
Based on the estimated propensity scores from equation (1.5), the treatment ef-
fect can be estimated via matching (Dehejia and Wahba 2002), stratification (Rosen-
baum and Rubin 1984; He and McDermott 2012), inverse-probability-weighting (IPW)
(Rosenbaum 1998), or covariate adjustment (Shepardson et al. 1999; Perkins et al.
2000).
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In practice, an often used propensity score matching is one-to-one match which
matches each treated (i.e. trt = 1) subject to an untreated (i.e. trt = 0) subject with
identical propensity score. However, since the propensity score is a continuous variable,
it is difficult to match a treated with an untreated with exactly identical propensity
score. Several propensity score matching algorithms have been proposed in this re-
gard. Commonly used propensity score matching algorithms include nearest neighbor
matching and clipper matching (Dehejia and Wahba 1999). Propensity score matching
is simple. In practice, PS matching is often used by researchers in various observa-
tional studies designs. However, shortcomings with propensity score matching include
(Shadish et al. 2002): large samples are required and overlap must be substantial. In
the case of low overlapping, a large number of samples will not be matched and have
to be discarded which could result in low estimation efficiency. In addition, low overlap
of propensity scores between the two groups may result in some severely imbalanced
covariates after matching. Propensity score matching could also match two dissimilar
subjects if the propensity score range used for matching is too broad and thus lead
to inexact matching. In practice, matching by propensity score may fail to remove all
bias due to confounders because samples may not be able to be matched sufficiently
closely (Hill 2008) and the within-pair differences in covariate values may still be large
(Rosenbaum and Rubin 1985).
Compared to the conventional stratified analysis method described previously, strat-
ification using propensity score becomes straightforward since all the samples are strat-
ified according to only ONE variable, i.e. the estimated propensity score, instead of
stratifyin all possible confounding variables one by one. This process greatly reduces
the complication and thus improves computation efficiency. If the treatment assignment
is strongly ignorable, then conditional on propensity scores by stratification will allow
us to obtain unbiased treatment effect estimate. By combining the stratum-specific
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treatment effect estimate, the weighting algorithm as shown below produces an overall
adjusted estimate of treatment effect:
αˆtrt =
K∑
j=1
nj
n
{ 1
n1j
n∑
i=1
trtiyiI(P̂Si ∈ Qj)− 1
n0j
n∑
i=1
(1− trti)yiI(P̂Si ∈ Qj)}
where K is the total number of strata n1j and n0j are the number of subjects in treated
and untreated groups within stratum j, respectively. nj = n1j + n0j is the number
of subjects in stratum j, and Qj denotes the propensity score range of stratum j.
Identifying individuals having exactly the same propensity value may be infeasible in
practice, stratification attempts to achieve groups where this at least holds approxi-
mately. Consequently, the treatment effect estimator via PS stratification may be a
biased estimator of the treatment effect, as some residual confounding within strata
may remain.
One benefit of propensity score stratification over matching is that it allows samples
who might not have a close enough matching mates on their propensity scores to be
included in some strata and not be discarded for the treatment effect estimation. No
matter propensity score matching or stratification, both methods need to determine the
propensity score cutoff for declaring participants and nonparticipants having exactly
“identical” propensity scores which is subjective. In practice, researchers often use
these two schemes due to their simplicity and easy to understand.
Inverse probability weighting (IPW) is another approach that weighs observations
from each group (i.e. treated and untreated) by the inverse of the probability of being
in that group (Rosenbaum 1998). Specifically, IPW estimates treatment effect as the
following:
αˆtrt =
1
n
n∑
i=1
{trti ∗ yi
P̂Si
− (1− trti) ∗ yi
1− P̂Si
}
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where w1i =
trti
nP̂Si
and w0i =
1−trti
n(1−P̂ Si)
are corresponding weights. One problem in prac-
tice with this estimator is that the weights do not necessarily add up to 1. Therefore,
another normalized version of IPW is used in practice:
αˆ(trt,norm) =
n∑
i=1
{trti ∗ yi
w1P̂Si
− (1− trti) ∗ yi
w0(1− P̂Si)
}
where w1 =
∑n
i=1
trti
P̂ Si
and w0 =
∑n
i=1
1−trti
1−P̂ Si
. The IPW estimators, no matter nor-
malized or not, are unbiased and consistent estimator of the treatment effect ∆ =
E(y(1))−E(y(0)) with y(1) and y(0) being the potential outcomes if the subjects have
had been assigned to the treated and untreated groups, respectively. In addition, these
estimators are also asymptotically normal under certain regularity conditions. Com-
pared with the stratification estimator, IPW estimator is more efficient (Lunceford and
Davidian 2004). In practice, in addition to being used as a confounding adjustment
tool, IPW is also often used by researchers to describe missing and censoring data.
Another convenient approach using the propensity score for confounding adjustment
is the covariate adjustment approach (e.g. D’Agostino 1998) by including the propensity
score as a covariate in the following regression model
y = α0 + αtrttrt + αPSP̂S +  (1.6)
Rosenbaum and Rubin (1983) had shown that the treatment effect estimate obtained
via the PS regression (1.6) is unbiased under the strongly ignorable treatment assign-
ment assumptions (1.3) and (1.4).
Propensity score regression is less sensitive to the misspecification of the functional
form (i.e. linear or quadratic) of the covariates as compared to the multiple regres-
sion method (Rubin 1997). Compared with other versions propensity score methods,
propensity score regression needs more restrictive assumption on the linearity between
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response and propensity score in addition to the strongly ignorable treatment assign-
ment assumption that the other propensity score methods also made. In contrast to
the regression model where all covariates are incorporated in the regression analysis,
propensity score regression reduces baseline information to a single composite sum-
mary of the covariates. In this sense, PS regression can be viewed as a dimension
reduction technique also. As compared with propensity score matching and stratifica-
tion, propensity score regression is simpler to use without the tedious procedure and
burden to match samples with close propensity scores. Propensity score regression re-
sults in increased precision for continuous outcomes and increased statistical power for
continuous, binary, and time-to-event outcomes (Steyerberg 2009). In the perspective
of applications, PS matching, stratification, and inverse probability weighting can be
used for observational study design and analysis while PS regression is mainly used
for the analysis. There exists many review literatures on propensity score methods
(e.g. D’Agostino 1998; P.C. Austin 2011). A review and comparison between different
versions of PS methods and multiple regression method can be found in Sturmer et al.
(2006).
1.1.3 Review of Clustered Data Analysis Methods
Besides the observational feature of medical record data where the treatment is
not randomly assigned, another distinctive characteristic of medical record data is that
they are clustered e.g. by physicians, clinics, hospitals, or insurance agencies. Further-
more, medical record data are not only clustered but also they could be multi-lever or
hierarchically clustered. For example, patients are clustered with physicians who are
also clustered by hospitals. As such, in the analysis of medical record data, both the
observational and clustering features should be taken into account to obtain the valid
treatment effect inference. The confounding control methods reviewed in the previous
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section are all for independent samples rather than clustered data.
The degree of clustering can be delineated in terms of correlation among the mea-
surements on units within the same cluster. Appropriate statistical models for clustered
data must explicitly describe and account for this correlation. With more and more
repeated measurements and longitudinal designs being used in various biomedical and
social economical studies, the interest in the analysis of clustered data continuously
grows. Many clustered data analysis techniques have been developed to deal with
different challenges. Mixed effects model (e.g. linear mixed effects model, general-
ized linear mixed effects model, etc) and the generalized estimating equations (GEE)
method are the two most widely used methods for the analysis of correlated data, which
we review below.
Mixed Effects Model
As noted in previous section, multiple regression model is a very versatile approach
in describing the relationship between the mean response and a set of independent co-
variates. However, the straightforward application of general regression method to the
clustered data like medical record data is not appropriate due to the lack of indepen-
dence among samples.
Many researchers have incorporated random effects into a wide variety of regression
models to account for dependent structures of responses and multiple sources of vari-
ations. A frequently used model for describing clustered continuous data is the linear
mixed effects model (e.g. Laird and Ware 1982; Lindstrom and Bates 1988) where
random effects are used to model the correlations among samples within each cluster:
yij = α0 + αtrttrtij + xijαx + ηi + ij (1.7)
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where xij and yij represent the covariates and the response outcome of subject j in clus-
ter i, respectively. The random variable ηis are independent and identically distributed
as N(0, σ2η) which denotes the cluster specific effect to account for mean differences
amongst clusters and the random error ij ∼ N(0, σ2) is assumed to be independent of
the ηis.
Examples of using mixed effects model for clustered data analysis can be found in
many biomedical and life science research (e.g. Petkova and Teresi 2002; Vaida and
Xu 2000). The above linear mixed model can be easily extended to generalized linear
mixed models (GLMMs) (Schall 1991; Zeger and Karim 1991; Breslow and Clayton
1993; Davidian and Giltinan (1995,2003); McCulloch and Searle 2001) for other types
of responses such as binary outcomes or count data.
Many real world data usually includes more than one level of clusters. For example,
in medical record data, many patients are treated by a physician and many physicians
work in a clinic/hospital. This leads to physicians as the first layer cluster who are
nested in the second layer cluster, i.e. clinics or hospitals. In the scenario of multilevel
or hierarchical clustering, a more complex mixed effects model is needed to account for
the heterogeneity of each cluster level. Conventionally, the following multilevel mixed
effects model (e.g. Sullivan et al. 1999; Goldstein et al. 2002) is used to model the
clustered data structures:
yijk = α0 + αtrttrtijk + xijkαx + ηi + ξij + ijk (1.8)
where xijk and yijk represent the observed covariates and the response outcome for
subject k nested in sub-cluster ij which is further nested in cluster i, respectively.
Cluster effects ηi, ξij, and random error ijk are mutually independent with each other
and are assumed to be normally distributed with mean 0. Each level cluster effect
accounts for the mean differences amongst clusters of the corresponding clustering
18
level.
To obtain the parameters estimates, maximum likelihood estimate is routinely used.
However, in the mixed effects model, besides the fixed effects covariates (i.e. trtij
and xij) which are observed, there exists random effects terms (i.e. ηi, ξij) which are
unobserved. Therefore, parameter estimates in mixed effects model can be treated as
a missing data problem, and the expectation-maximization (EM) algorithm (Dempster
et al. 1977), a well-known algorithm for maximum likelihood estimation based on
incomplete data, can be used for parameter estimates.
In addition to the routine normality assumption made on the random effect, it
is also assumed that the random effect is independent of other fixed effects terms.
All these assumptions are made for the simplicity of statistical analysis and may not
hold for many real applications including the medical record data where the treatment
assignments are clustered. However, violations of these assumptions can result in severe
biased estimates and invalid statistical inferences (Verbeke and Lesaffre 1996).
Generalized Estimating Equations
Another frequently used method for dealing with dependent observations is through
what has become generally known as generalized estimating equations (GEEs) (e.g.
Liang and Zeger 1986; Hardin and Hilbe 2003). GEEs can be regarded as an extension
of quasi-likelihood models for independent measurements. This modeling scheme has
often been applied in biomedical research (e.g. Cologne et al. 1993; Hanley et al. 2003).
A notable characteristic of GEE approach is that under mild regularity conditions,
the parameter estimates from the GEE are consistent even when the covariance struc-
ture is misspecified. The primary interest of GEE is on estimating the average response
over the population (i.e. marginal response) rather than the regression parameters that
would enable the estimation of the effect of changing one or more covariates on a given
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individual. The parameter β estimates, i.e. βˆ, of GEE are obtained by solving the
following equation:
n∑
i=1
D
′
iV
−1
i (yi − µi) = 0 (1.9)
where Di is the ni × p matrix of derivatives of µi with respect to β and Vi is treated
as known up to certain parameters (referred as working covariance matrix) and µi is
the vector of mean responses with elements of µij(β) = g
−1(xijβ). The covariance
estimates for β estimates, i.e. Ĉov(βˆ) can be obtained via the sandwich estimator.
Apart from the aforementioned commonly used methods for dealing with clustered
data, there exists few research using mixed effects PS model by including the unobserved
cluster effect in the logistic regression model to adjust for the treatment assignment
heterogeneity confounding factors (e.g. Thoemmes and West 2011) where the normality
is assumed for the cluster effects.
1.2 Proposed Research for Medical Record Data
1.2.1 Robust Two-Stage Variance Estimation for PS Regression Models
Propensity score (PS) is commonly used in observational studies for adjusting con-
founding factors when comparing the effectiveness of different treatments. Among
different PS-based methods, the PS covariate adjustment (a.k.a. PS regression) which
uses the estimated PS as a covariate in the second stage regression model has been fre-
quently used in clinical research. In practice, researchers tend to make their inference
on the treatment effect based on the default variance estimate from the second stage
regression model. This variance estimate, however, does not take into consideration
of the fact that the propensity score itself is an estimated quantity. Without proper
correction, the default variance estimate could be biased. To address this problem, we
jointly model the treatment assignment and the response variable under a two-stage
20
regression framework. The asymptotic results for the treatment effect estimator are
established, based on which a robust variance estimator is developed.
Specifically, we regard the propensity score regression models as a two-stage proce-
dure shown below:
Stage 1: trti | xi ∼ f(trti | xi,θ1) (1.10)
Stage 2: (yi, trti) | PS(xi,θ1) ∼ f(yi | trti, PS(xi,θ1),θ2)f(trti | PS(xi,θ1)) (1.11)
where yi is the response variable, trti is the treatment assignment (1 for treated and
0 for untreated), and xi is the covariate vector for the ith individual (i = 1, 2 · · · , n),
respectively. θ1 and θ2 are the parameter sets associated with Stage 1 and 2 models.
The unknown PS score, PS(x,θ1)(= Pr(trt = 1 | x,θ1)), is a function of x and θ1.
Based on this two-stage regression framework, we establish the asymptotic result for
θˆ2, i.e. the parameter estimate for Stage 2 model which includes the treatment effect
estimate, our primary interest. From the asymptotic distribution of θˆ2, we propose the
covariance estimator.
1.2.2 A Semi-Nonparametric PS (SNP-PS) Model for Clustered Data
The treatment allocation in medical record data is non-randomly made by physi-
cians according to various factors observed and/or unobserved (e.g. physician’s factor,
etc.), these factors could also completely or partially impact the disease outcomes.
Consequently, samples in medical record data are clustered with respect to physicians.
As a result, the mixed effects model is a natural approach for medical record data
with the heterogeneity being included as a random effect term. With the attractive
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features of propensity score adjustment approach for confounding adjustment, we pro-
pose a generalized mixed effect propensity score model to deal with the heterogeneity
in treatment assignment process. Few current literatures deal with the random effects
in logistic regression model (e.g., Thoemmes and West 2011) for propensity score esti-
mation. However, a critical assumption made for the conventional mixed effects model
is that the cluster effect term is normally distributed which may be too restrictive for
real world medical record data. The validity of this assumption is hard to check for
real applications and violation of the assumption will lead to invalid propensity score
estimation and result in biased treatment effect estimate. Indeed, the normality as-
sumption often does not hold in practice due to many confounding factors and complex
heterogeneity involving in the treatment allocation process. To be more flexible in
capturing the heterogeneity structure in the treatment allocation process for medical
record data, we relax the normality assumption on the random effect in the generalized
mixed effects model with an unspecified random effect term. With the PS regression
framework, the estimated PS from the proposed model is incorporated to adjust the
heterogeneity confounding and obtain the treatment effect estimate that could be bi-
ased if the conventional statistical methods are used where the treatment assignment
heterogeneity is incorrectly modeled.
Specifically, we consider the following semi-nonparametric (SNP) logistic regression
model for the propensity score estimation:
logit(Pr(trtij = 1 | xij)) = β0 + xijβx + ηi (1.12)
Instead of assuming that the ηis are normally distributed, we make no specific assump-
tion on the form of the distribution of the ηis except that it is a smooth density function
f(η). We approximate the density function f(η) by K+1 terms of Hermite polynomial
multiplied by a normal density (Gallant and Nychka 1987). Once the PS scores are
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estimated from the above model, then the rest of the analysis will follow the traditional
PS regression procedure.
Estimation of propensity score based on the SNP-PS model is challenging. The
primary difficulty results from the fact that the likelihood function of model (1.12) is
complicated without closed analytic form since it involves the integration over a nonlin-
ear integrand. To resolve this problem, various approximation techniques (e.g. Laplace
approximation) were developed to avoid the integration (Schall 1991; Breslow and Clay-
ton 1993). However, several research (Breslow and Lin 1995; Lin and Breslow 1996)
shows that approximations based approaches may yield biased fixed effect estimates,
particularly for the binary responses. Alternative approaches (Lee and Nelder 1996;
Jiang 1999) were proposed to resolve this difficulty. On the other hand, methods were
developed to conduct the integrations via the Markov chain Monte Carlo techniques
(Zeger and Karim, 1991) and Monte Carlo EM (MCEM) algorithms (McCulloch 1997;
Booth and Hobert 1999). For example, an approach proposed by Booth and Hobert
(1999) is based on using rejection sampling technique to generate samples from the
appropriate conditional distribution. The advantage of this approach is that it allows
to evaluate the Monte Carlo error at each iteration and automatically increase the
Monte Carlo sample size accordingly and thus reduce the unnecessary computational
workload.
Chen et al. (2002) extend the rejection sampling scheme of Booth and Hobert (1999)
with a double rejection Monte Carlo sampling approach for accessing the conditional
likelihood for the generalized mixed effects model. However, the Monte Carlo sampling
suffers with Monte Carlo errors if the random sample number is not large enough (Booth
and Hobert 1999; Chen et al. 2002). Heavy computation workload associated with the
large Monte Carlo sample size prohibits the application of the MCEM sampling to the
medical record data with hundreds of thousands observations. Furthermore, the second
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rejection sampling component may suffer a low acceptance rate in some applications,
particularly for binary data when the proportions of 0 and 1 responses within a cluster
are severely imbalanced (Chen et al. 2002). To avoid these difficulties, alternatively,
we propose a numerical integration approach, i.e. adaptive quadrature integration,
to calculate the conditional likelihood for the proposed SNP-PS model (1.12). It can
be shown that under the assumption of no other unmeasured confounding covariates,
the treatment effect estimate from the proposed SNP-PS framework is unbiased and
asymptotic normal.
1.2.3 A Flexible Mixed Effects PS (FM-PS) Model for Clustered Data
When medical record data are multilevel clustered, the robust SNP-PS model pro-
posed above is computationally too intensive to be applied to huge multilevel clustered
data. More computationally efficient PS models are needed. Note that in the SNP-PS
model, the heterogeneity cluster effects are dealt with in the mixed effects PS model
which is computationally expensive. Alternatively, we propose a flexible linear mixed
effects propensity score (FM-PS) model which does not take into account the hetero-
geneity cluster effects in the PS model but instead leaves the heterogeneity adjustment
to the subsequent PS covariate adjustment model.
Extra covariates are introduced in FM-PS models based on the observed treatment
assignment and the estimated PS to model the correlation structures between the ran-
dom cluster effects and the fixed effect terms such that only the standard simple mixed
effect model is needed to fit and obtain the treatment effect estimate. The treatment
effect estimate equivalence is established between FM-PS model and the fixed effects
PS model (FE-PS) where the cluster effect is treated as the fixed effect by using dummy
variables. The equivalence of treatment effect estimate provides the justification that
the proposed FM-PS relaxes both the independence and normality assumptions for the
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random cluster effects that the traditional clustered data modeling frameworks made
but are generally not held by the real world medical record data. Therefore, the pro-
posed FM-PS is not only robust for the random effect density structure due to clustering
but also flexible to the correlation between the random effects and other fixed effects
confounding covariates. More importantly it is applicable for huge dataset like medical
record data for practical use.
As all other propensity score based methods, the standard variance estimation for
FM-PS models are not valid either. Accordingly, we propose a cluster bootstrapping
procedure to obtain the valid variance estimate empirically.
1.3 Innovation of Proposed Research
1.3.1 Significance of Two-Stage Variance Estimation
Even though the treatment effect estimate from the PS regression model (1.6) is un-
biased, the variance estimation directly from the PS regression model could be severely
biased. In contrast, the proposed two-stage variance estimation scheme for propensity
score regression models provides a valid variance estimation approach that corrects the
bias of the commonly used default variance estimate from the second stage PS regres-
sion model. The default variance estimation ignores the fact that the propensity score
is an estimated quantity instead of the observed covariate. Without jointly modeling
the response and the treatment assignment will lead to the default variance estimation
which could be severely biased as we will see in our simulation studies. The essence of
the proposed two-stage variance estimation is the jointly modeling of the response and
the treatment assignment given the propensity score. This modeling scheme takes the
consideration of the estimation error for the parameters of the first stage model and
thus the estimation error of the propensity score.
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1.3.2 Significance of SNP-PS
The proposed SNP-PS model for dealing with the heterogeneity of treatment al-
location provides a uniform approach to adjust the nonparametric heterogeneity con-
founding in a robust fashion without the restrictive assumptions. Unlike many existing
statistical methods, we extend the prevailing propensity score adjustment approach by
including a random effect term without specifying any density distribution in the PS
model such that only a simple linear regression is needed to assess the treatment effect.
Therefore, SNP-PS is more robust to the distribution misspecification of the random
effects.
One challenge with the generalized mixed effects model is that there exists no an-
alytic closed form for the log-likelihood function. The double rejection Monte Carlo
sampling EM algorithm of Chen et al. (2002) suffers slow convergence and high Monte
Carlo errors, which prevents its practical usage for large medical record datasets. Fur-
thermore, the double-rejection sampling scheme of Chen et al. (2002) may have low
acceptance rate for binary data when the cluster cell size is imbalanced. Alternatively,
we propose a computationally efficient numerical integration approach, i.e. adaptive
quadrature integration, to avoid the large Monte Carlo errors if the sampling scheme is
used and the potential low acceptance rate of the second rejection sampling component.
In summary, the innovations of the proposed SNP-PS framework for the treatment
effect estimate purpose of medical record data includes: First, the proposed SNP-PS ap-
proach robustly models the heterogeneity of treatment allocation process and includes
the traditional normality assumption as a special case. Second, the proposed adaptive
quadrature integration scheme significantly reduces the computational workload and
the potential large Monte Carlo errors in the sampling based method for the parameter
estimates in generalized mixed effects model. Third, we propose a valid variance esti-
mator for SNP-PS regression model that corrects the biased variance estimation based
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on the default variance estimator.
1.3.3 Significance of FM-PS
Medical record data could include hundreds of thousands or even millions of medical
records integrated from various resources with the treatments assigned by a number of
doctors and patients treated at many different clinics or hospitals. The multilevel clus-
tering feature of medical record data further complicates their analysis when treatment
effect is intended since it invalidates the crucial independence assumption for the out-
comes that many statistical models make. Mixed effects model is the most widely used
statistical tool to deal with the clustered and correlated data. However, two impor-
tant assumptions for the random effects terms made in the conventional mixed effects
models are the independence with respective to other fixed effect terms including the
treatment assignment and the normality. These assumptions could be too restrictive for
the real world medical record data. We propose a flexible linear mixed effects propen-
sity score model to deal with the complicated correlation structures of medical record
data conveniently and relax these two assumptions by establishing the equivalence of
treatment effect estimates obtained from FM-PS and the dummy variable fixed effects
PS (FE-PS) regression model. This equivalence not only relaxes the assumption on
the independence between the random effect terms and the fixed effect terms in linear
mixed effects model but also the normality assumption for the random effect term.
The novelties of the proposed FM-PS model include: First, it relaxes the very
restrictive independence assumption made in mixed effects model for the random effects
terms with respect to other fixed effect terms in modeling the clustered data. Second,
it flexibly models the complicated correlation among the confounding covariates of
medical record data by incorporating them in the propensity score model and including
the proportion of subjects in the treated group and the mean of the estimated propensity
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score of each cluster in a simple linear mixed effects model without the burdens to model
the details of the covariance structure among the random effect and other covariates.
Third, FM-PS is computationally efficient as compared to the FE-PS method which
is prohibited in the existence of hundreds thousands clusters like many medical record
data. Therefore, FM-PS is applicable in practice for the huge clustered dataset. Fourth,
a novel cluster bootstrapping procedure to obtain the valid variance estimation for the
treatment effect estimate from FM-PS is proposed. Furthermore, a likelihood ratio test
statistic is proposed to allow for selecting the efficient and unbiased treatment effect
estimate from between FM-PS and SM-PS models.
1.4 Outline of The Remaining of Dissertation
Due to the limitations of existing statistical methods, in this dissertation, new
statistical methods are developed for treatment effectiveness inference. The methods
focus on addressing some issues of heterogeneity in treatment assignment and multilevel
clustering settings for medical record data in comparative effectiveness research. It is
the goal to develop robust and efficient statistical methods to deal with these limitations
under these scenarios by considering the complicated data structures and relaxing some
unrealistic assumptions for real applications. In addition, the statistical properties for
the proposed methods and models are extensively explored. Overall, the structure of
this dissertation is arranged as the following:
Chapter One: provides the introduction of medical record data, the existing statistical
methods for the analysis of these data, and the proposed methods due to the limitations
of existing methods.
Chapter Two: describes the details of the proposed two-stage variance estimator for
PS regression models and its performance under finite sample settings via simulation
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studies. The asymptotic results of PS regression models are established in this chapter.
Chapter Three: delineates the details of the proposed semi-nonparametric propensity
score (SNP-PS) approach for clustered observational data and its performance under
finite sample settings. Practical application of SNP-PS regression method is demon-
strated via a real data analysis. In addition, the mathematical derivations for the
properties of SNP-PS under large sample scenarios are given in this chapter.
Chapter Four: presents a flexible linear mixed effects propensity score (FM-PS)
model for multilevel clustered data. Simulation studies are used to demonstrate FM-PS
performance under finite sample setups and different model misspecification settings.
Justification for FM-PS approach to model the multilevel clustered data for treatment
effectiveness inference is given via cluster bootstrap resampling scheme.
Chapter Five: discuss the future research for the proposed methods and the potential
extensions.
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Chapter 2
A Robust Two-Stage Variance Estimation for PS Regression Analysis
2.1 Introduction
Randomized controlled trial (RCT) is regarded as the gold standard to establish
causal effects of drug efficacy. In completely randomized clinical trials, treatments
are randomly assigned and the proper randomization procedure guarantees that there
exists no systematic difference among subjects for their baseline features in different
treatment groups. However, RCTs have their limitations and can not always be con-
ducted in practice (e.g. Kramer and Shapiro, 1984; Johnston et al, 2006). Data from
observational studies or electronic medical records, on the other hand, are readily avail-
able and often used as alternatives for the evaluation of therapy effectiveness and drug
efficacy.
The key difference between data from the observational study and RCT is that the
treatment assignment under the real world observational design is not random. Instead,
the treatment allocation of each subject is primarily made by researchers according
to the subject’s characteristics (e.g. physical condition, disease severity, etc). The
non-random treatment assignment could lead to imbalanced baseline characteristics. If
unaccounted for, this could bias the treatment effect estimate and result in the problem
known as confounding issue that could lead to erroneous scientific conclusions. Among
proposed methods for confounding adjustment, multiple regression and various version
of propensity score (PS) methods are commonly used in practice.
If the multiple regression model is correctly specified, the treatment effect estimator,
i.e. least square estimate (LSE), provides the best linear unbiased estimate (BLUE)
for the treatment effect, which can be regarded as the benchmark for evaluating the
efficacy of different interventions and procedures in comparative effectiveness research.
Alternatively, the PS method (Rosenbaum and Rubin 1983) provides a simple and
straightforward way to control confounding factors in non-randomized settings. PS
methods are increasingly used as alternatives of multiple regression (e.g. Czajka et al.
1992; Schneeweiss et al. 2002; Bang and Robins 2005) due to its simplicity and robust-
ness. A propensity score is defined as the conditional probability of a subject being
assigned to a particular treatment in a study given a set of observed covariates. Rosen-
baum and Rubin (1983) had shown that under certain conditions, the distributions of
measured baseline covariates for the treated and untreated subjects are similar condi-
tional on any given propensity score. That is, subjects with the same propensity scores,
they have the same distributions for the baseline covariates no matter if they come from
the treated or untreated groups. They demonstrated that if the treatment assignment
is strongly ignorable (i.e. condition (1.3) of Rosenbaum and Rubin, 1983), conditional
on propensity scores allows one to obtain an unbiased treatment effect estimate.
In practice, the propensity score is unknown and commonly estimated via the logistic
regression model. Once the propensity scores are estimated, the treatment effect can
be estimated via matching (e.g. Tanasescu et al. 2002; Neily et al. 2010; Rothberg et
al. 2010), stratification (e.g. Rosenbaum and Rubin 1984; He and McDermott 2012),
inverse-probability-weighting (IPW) (e.g. Do and Finch 2008), or covariate adjustment
(e.g. D’Agostino 1998). PS regression analysis where the estimated propensity score
used as a covariate in the second stage regression model is frequently used in clinical
research (e.g. Wang and Donnan 2001; Weitzen et al. 2004). Analysis results based
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on the PS regression constantly appear in top scientific journals such as JAMA and
NEJM (e.g. Koch et al. 2008; Shaw et al. 2008; Eklind-Cervenka et al. 2011; Jackson
et al. 2012; Bangalore et al. 2012).
While the PS covariate adjustment provides an efficient and robust treatment effect
estimate, the variance estimation of the treatment effect estimate from the standard
PS regression model is biased. In practice, researchers routinely base their inference
on the default variance estimate from the second stage regression model, ignoring the
fact that the PS is a estimated quantity. We recognize that the PS regression approach
can be viewed as a two-stage procedure used in a wide class of empirical applications
where unobserved regressors, such as expectations, are estimated from an auxiliary
statistical model. It is well known that the second-step estimated standard errors
and related test statistics based on these procedures are incorrect (Murphy and Topel
1985). In this chapter, we jointly model the distribution of the response and treatment
assignment given the propensity scores and develop a simple yet general method for
calculating asymptotic standard errors in two-stage models for PS regression analysis.
The joint modeling scheme resolves the biased variance estimation issue in the standard
PS regression model by taking into account the stochastic errors in the parameter
estimates when the propensity scores are estimated.
Similar concerns on the variance estimates have been noticed for other PS-based
methods and improved variance estimators have been proposed for PS inverse prob-
ability weighting (e.g. Lunceford and Davidian 2004; Williamson et al. 2012), and
matching (e.g. Abadie and Imbens 2011). This chapter fills in a gap in variance esti-
mation for the PS regression method. Our simulation results further demonstrate the
importance of using the proposed two-stage regression model in practical comparative
effectiveness research.
The rest of this chapter is organized as follows. In Section 2, we provide some
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background introductions on existing PS methods. In Section 3, we introduce the PS
regression model under the two-stage analysis framework. We then derive the asymp-
totic result under the proposed two-stage PS regression scheme. Based on the asymp-
totic result, we propose a robust and improved variance estimator. In Section 4, we
conduct simulations to evaluate the finite sample performance of the proposed variance
estimator under various confounding settings and model misspecification scenarios. In
addition, to appreciate the usefulness of PS regression method in comparative effec-
tiveness research, we compare the performance of our proposed two-stage PS regression
method with other existing PS methods, in along with the benchmark method, i.e.
multiple regression. We then apply the proposed method to a real data analysis in Sec-
tion 5 to demonstrate the practical application. We end the chapter with discussions
in Section 6.
2.2 Existing Methods
We first introduce some notations. Let yi be the response variable, trti be the
binary treatment assignment status (1 for treated and 0 for untreated), and xi be other
observed covariates with dimension of p for individual i (i = 1, · · · , n). The observation
for each subject consists of (yi, trti,xi). In this chapter, we focus on the situation where
the response variable is continuous and depends on treatment assignment with effect
of αtrt and other observed covariates x:
E(y | trt,x) = α0 + αtrt ∗ trt+ x ∗αx
Our primary interest is the treatment effect, αtrt, estimate and its variance estimation.
Under the counterfactual framework of Rosenbaum and Rubin (1983), the primary
interest is the so-call average treatment effect ∆ ≡ E(y(1)) − E(y(0)) where y(1) and
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y(0) are the potential outcomes if the subject had been assigned to the treated and un-
treated group, respectively. In reality, y(1) and y(0) can not be observed simultaneously.
Instead, they are related to the observed response y as: y = trt ∗ y(1) + (1− trt) ∗ y(0).
Under the strongly ignorable treatment assignment assumption of Rosenbaum and Ru-
bin (1983), i.e. (y(1), y(0)) ⊥ trt | x, there exist equivalence between ∆ and αtrt which
can be easily checked: αtrt = E(y | trt = 1,x) − E(y | trt = 0,x) ⇒ αtrt = E(αtrt) =
E(E(y | trt = 1,x)) − E(E(y | trt = 0,x)) = E(E(y(1) | x)) − E(E(y(0) | x)) =
E(y(1) | x)− E(y(0) | x) = ∆.
With the strongly ignorable assumption, the confounding factors can be controlled
via a simple statistic, i.e. the propensity score (PS). PS is defined as the conditional
probability for a unit to receive the treatment given all other observed covariates, i.e.
PSi ≡ Pr(trti = 1 | xi). That is, under the strongly ignorable assumption, we have:
(y(1), y(0)) ⊥ trt | PS(x) as shown by Rosenbaum and Rubin (1983). In practice, the
propensity score is unknown and usually estimated by the logistic regression model:
logit(PS) = xβ. With the parameters β estimated, the propensity score can be esti-
mated as:
P̂Si =
exp (xiβˆ)
1 + exp (xiβˆ)
and the treatment effect can be estimated via PS matching, stratification, IPW, or
covariate adjustment.
Under the standard PS regression framework, the treatment effect estimate and its
corresponding variance estimation are obtained by fitting the following simple linear
regression model:
yi = α0 + αtrttrti + α1P̂Si + i (2.1)
where P̂Si is the estimated propensity scores. We denote the treatment effect estimator
from the standard PS regression model (2.1) as αˆtrt,PSR. Even though αˆtrt,PSR is
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unbiased under the strongly ignorable and linearity assumptions, the default variance
estimate (denoted as V̂ ar(αˆtrt,PSR)) from the standard PS regression model (2.1) is
biased as will be demonstrated by the extensive simulation studies in Section 2.4.
2.3 Two-Stage Framework for PS Regression
To delineate the proposed variance estimator, we first express the PS regression
analysis as a two-stage regression model shown below:
Stage 1 Model: trti | xi ∼ f(trti | xi,θ1)
Stage 2 Model: (yi, trti) | PS(xi,θ1) ∼ f(yi | trti, PS(xi,θ1),θ2)f(trti | PS(xi,θ1))
where θ1 and θ2 are the parameter sets associated with Stage 1 and 2 models. The
unknown PS score, PS(x,θ1)(= Pr(trt = 1 | x,θ1)), is a function of x and θ1.
The log-likelihood of Stage 1 model is
l1(θ1) =
n∑
i=1
l1,i(θ1) =
n∑
i=1
log f(trti | xi)
=
n∑
i=1
{trti ∗ log(PSi) + (1− trti) ∗ log(1− PSi)} (2.2)
where PSi = Pr(trti = 1 | xi,θ1). If the logistic regression model is used in Stage 1
model, then PSi =
exp(β0+xiβ)
1+exp(β0+xiβ)
and θ1 = (β0,β)
′
.
The log-likelihood of Stage 2 model is
l2(θ1,θ2) =
n∑
i=1
l2,i(θ1,θ2) =
n∑
i=1
log f(yi, trti | PSi)
=
n∑
i=1
log {f(yi | trti, PSi,θ2)f(trti | PSi)}
=
n∑
i=1
log f(yi | trti, PSi,θ2) +
n∑
i=1
l1,i(θ1). (2.3)
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f(yi | trti, PSi,θ2) = φ(yi;α0 + αtrttrti + α1PSi, σ2) where function φ(y;µ, σ2) is the
normal density function with mean µ and variance σ2. Thus, θ2 = (α0, αtrt, α1, σ
2)
′
.
In Stage 1 model, the parameter θ1 and PS score, PSi, are first estimated via
equation (2.2) as θˆ1 = argmaxθ1l1(θ1) and P̂Si = PS(xi, θˆ1), respectively. Then the
estimated PS scores are plugged into equation (2.3) for estimating θ2, which contains
the treatment effect αtrt, our primary interest. Specifically, in the second stage analysis,
θˆ2 = argmaxθ2l2(θˆ1,θ2). Note that when PSis are replaced by P̂Sis, maximizing the
likelihood l2(θ1,θ2) reduces to maximizing the likelihood of the following simple linear
regression model:
yi = α0 + αtrttrti + α1P̂Si + i,
i.e., the standard PS regression model. We note that the term l1,i(θ1) in l2,i(θ1,θ2) plays
no role in estimating θ2 but it is a critical term for the variance estimation. Ignoring
this term will result in variance estimate very close to the one given by the standard
PS regression model (2.1), i.e. V̂ ar(αˆtrt,PSR), which tends to be biased. We denote the
treatment effect estimator for parameter αtrt as αˆtrt,P under our proposed two-stage
framework. Under some regularity conditions, we have the following asymptotic results
for the treatment effect estimate αˆtrt,P :
Theorem 2.3.1. The treatment effect estimator αˆtrt,P is asymptotically normally dis-
tributed with,
√
n(αˆtrt,P − α∗trt)→ N(0, σ222)
where σ222 is the second diagonal element of the covariance matrix Σ given as the fol-
lowing:
Σ = V2 + V2[CV1C
T −RV1CT −CV1RT ]V2
with V −11 = E
{(
∂l1
∂θ1
)(
∂l1
∂θT1
)}
, V −12 = E
{(
∂l2
∂θ2
)(
∂l2
∂θT2
)}
, C = E
{(
∂l2
∂θ2
)(
∂l2
∂θT1
)}
,
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and R = E
{(
∂l2
∂θ2
)(
∂l1
∂θT1
)}
. Under the strongly ignorable condition (1.3) and the lin-
earity assumption in COROLLARY 4.3 of Rosenbaum and Rubin (1983), α∗trt can be
replaced by αtrt, the true marginal treatment effect.
The proof of Theorem 2.3.1 can be found in Appendix I. The above theorem provides
us a basis for a modified variance estimator. To estimate the covariance matrix Σ, we
propose a sample estimate of Σ as the following:
Σˆ = Vˆ 2 + Vˆ 2[CˆVˆ 1Cˆ
T − RˆVˆ 1CˆT − CˆVˆ 1RˆT ]Vˆ 2
where Vˆ
−1
1 =
1
n
∑n
i=1
∂l1,i
∂θ1
∂l1,i
∂θT1
| ˆθ1 , Vˆ
−1
2 =
1
n
∑n
i=1
∂l2,i
∂θ2
∂l2,i
∂θT2
| ˆθ1, ˆθ2 , Cˆ =
1
n
∑n
i=1
∂l2,i
∂θ2
∂l2,i
∂θT1
| ˆθ1, ˆθ2 and Rˆ =
1
n
∑n
i=1
∂l2,i
∂θ2
∂l1,i
∂θT1
| ˆθ1, ˆθ2 , respectively. Matrix Σˆ provides
a good estimate to Σ as can be demonstrated by the simulation studies below. The
proposed variance estimator of the treatment effect estimate αˆtrt,P is σˆ
2
22 which is the
second diagonal element of covariance matrix Σˆ.
2.4 Simulation Studies
To evaluate the performance of the proposed two-stage regression estimator versus
other existing estimators, we conduct simulation studies under various confounding
settings as described in the following. Specifically, we compare the treatment effect
estimator using the proposed two-stage model, i.e. αˆtrt,P , versus the estimates from PS
stratification (αˆtrt,S), IPW (αˆtrt,IPW ), multiple regression (αˆtrt,LSE), and the standard
PS regression (αˆtrt,PSR).
Treatment allocation model: In our first set of simulations, the treatment assign-
ment is based on the following mechanism:
logit{PSi(= P (trti = 1 | x1i))} = x1iβx, (2.4)
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where the confounding covariate vectors x1i = (x1i,1, · · · ,x1i,p)T have p independent
covariates. We let half of the confounding covariates be binary and the other half
be continuous. For the binary variables, they follow Bern(0.5) and the continuous
variables are simulated from N(0, 1). For the ease of description, we let each parameter
βx,j in βx = (βx,1, · · · , βx,p)′ be randomly generated from N(0, 1) but they are fixed for
all the subsequent simulations.
Data generating model: The responses are generated based on the following data
generating process:
yi = αtrttrti + x1iαx + i, (i = 1, · · · , n) (2.5)
where i ∼ N(0, 1) and is independent of trti and x1i. The true treatment effect αtrt
is fixed at 0.5. The effect of each confounding covariate, αx,j (j = 1, · · · , p), is also
generated from N(0, 1).
In observational studies, there may exist many covariates and we may not know
which are the true confounding factors and which are not. It is common to include
most if not all of them in the analysis. To mimic the real world observational data,
in addition to the (true) confounding covariates x1i, we also simulate an additional set
of q (q ≥ 0) nuisance variables, x2i. Again, among the q nuisance variables, half of
them are generated from Bern(0.5) and the other half follow N(0, 1). These nuisance
variables have no effects on either the response variable y or the treatment assignment
trt. However, we include the observed covariates xi = (x
T
1i,x
T
2i)
T in all analysis to
mimic the data analysis in practice. For cases where q = 0, only the true confounding
covariates are included, the best scenario that could happen in practice.
Table 2.1 summarizes simulation results with varying sample size n, the number
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of confounding covariates p and the number of nuisance variables q. For each simu-
lation setup, the results are based on 1000 simulations. Column “Mean(αˆtrt)” repre-
sents the average treatment effect estimate, column “Monte Carlo SD(αˆtrt)” shows the
Monte Carlo standard deviation of the treatment effect estimate, and column “Average
SE(αˆtrt)” presents the average standard error for the treatment effect estimate.
Inspecting Table 2.1 reveals that the treatment effect estimate is very close to the
true effect size 0.5 in all situations indicating the unbiasedness of treatment effect es-
timate under different analysis schemes. The value in column “Monte Carlo SD(αˆtrt)”
can be viewed as the true error of treatment effect estimate for each estimator. A closer
inspection of this column for the first part of Table 2.1 clearly shows that the stan-
dard deviations for the LSE, the standard PS regression and the proposed two-stage
regression are all close to each other. This indicates that the PS regression based treat-
ment effect estimators can be almost as efficient as the one from the multiple regression
method. A further inspection of this column reveals that both PS stratification and
IPW methods provide less efficient estimates.
Most importantly, comparing the column of “Average SE(αˆtrt)” with the column
of “Monte Carlo SD(αˆtrt)” for the standard PS regression estimator, i.e. αˆtrt,PSR, we
notice that there exist big differences. The former is consistently larger than the latter,
indicating the variance estimation from the standard PS regression is upwardly biased.
This problem remains unchanged even when the sample size increases. For example, in
the scenario of sample size 500, p = 10, and q = 0, the mean standard error 0.276 is more
than doubled from the standard deviation 0.119. When the sample size is increased to
5000, the mean standard error 0.086 is still more than double of the standard deviation
0.037. The invalid variance estimation of the standard PS regression model is also
reflected in the 95% confidence interval (CI) coverage which is always far away from
95% in all simulation settings. In contrast, the standard error based on the proposed
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two-stage framework is always very close to the standard deviation in all simulation
settings no matter if the sample size is large or not. Furthermore, the corresponding
95% CI coverage for the proposed two-stage estimator, i.e. αˆtrt,P is close to 95% in all
simulation settings and further confirms the unbiased variance estimation.
To further investigate the robustness property of the proposed variance estimator,
we conducted two additional simulations by varying the data generating model and the
treatment allocation model. Specifically, we consider the following two model misspec-
ification scenarios:
Misspecification of PS model: we keep the data generating model (2.5) the same
but change the treatment assignment from the logistic regression model (2.4) to the
following allocation mechanism:
logit{PSi(= P (trti = 1 | x1i))} = β0 + β1x21i,1 + x1iβx
where βx = (βx,1, βx,2, · · · , βx,p)′ and x1i = (x1i,1, x1i,2, · · · , x1i,p), respectively. That is,
the first continuous covariates x1i,1s affect the treatment assignment trt both linearly
and quadratically. However, when estimating the propensity scores, we only include
the linear terms of all observed covariates xi in our analysis. In this sense, the PS
model is misspecified but not the multiple regression model.
Misspecification of multiple regression model: we keep the treatment allocation
mechanism (2.4) but change the data generating model as follows:
yi = αttrti + α1x
2
1i,1 + x1iαx + i.
Here αx = (αx,1, αx,2, · · · , αx,p)′ and x1i = (x1i,1, x1i,2, · · · , x1i,p), respectively. In this
simulation, the first continuous covariates x1i,1s affect the response yi both linearly and
quadratically. When fitting the multiple regression model, we still use the linear term of
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all observed covariates. That is the multiple regression model is misspecified. However,
the PS model is not misspecified. For each of the model misspecification scenario, we
consider two sample size scenarios, i.e. 500 and 5, 000. The simulation results are
presented in Table 2.2.
From the first half of Table 2.2 where the PS model is misfitted, we note that the
treatment effect estimates based on different estimators are quite close to the true effect
size except the PS stratification estimator. This observation keeps unchanged when the
sample size increases from 500 to 5000. It is evident from Table 2.2 that the variance
estimation via the standard PS regression is far away from the true variance. However,
the variance estimate based on the proposed two-stage method is always close to the
true variance.
In the second half of Table 2.2 where one of the covariates affects the response
quadratically, we notice that the treatment effect estimates from PS stratification,
IPW, and multiple regression methods all suffer biasness. The biasness from IPW gets
reduced when the sample size increases while the biasness does not get improved for PS
stratification and multiple regression. On the other hand, the treatment effect estimates
from the standard PS regression and the proposed two-stage regression framework are
unbiased. However, the variance estimation via the standard PS regression is severely
upward biased from the true one. In contrast, our proposed method always provides
an accurate variance estimate for the true variance.
With the extensive simulation studies, our overall observation is that the treatment
effect estimators based on both the standard PS regression method and the proposed
two-stage regression scheme provide very accurate treatment effect estimate even when
the model is misspecified. They can be as efficient as that of BLUE based on the
multiple regression model when the model is correctly specified. However, the variance
estimation of the treatment effect estimate under the standard PS regression scheme
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is always biased. In contrast, the proposed variance estimation based on the two-stage
framework is consistently close to the true variance in all scenarios considered.
2.5 Real Data Analysis
To demonstrate the usage of the proposed method, we applied it to the analysis of
a breast cancer study by the German Breast Cancer Study Group (Rauschecker et al.
1995). The study originally was intended as a randomized trial but it had to be changed
to an observational study due to the low randomization rate. The primary objective for
this study was to compare two breast cancer treatment procedures, i.e. the mastectomy
(trt = 0) versus lumpectomy (breast conservation, trt = 1), on the effect of quality of
life (QoL) for the breast cancer patients after the surgery. A subset of the data for this
study can be obtained from “nonrandom” R package with 646 subjects. The primary
outcome was the performance status (PST) 9 months after surgery, which is quantified
as a score between 0 and 100 based on the 25 QoL questionnaire responses, where
higher scores reflect better QoL. Covariates other than the therapies (i.e. mastectomy
vs. lumpectomy) including patient age (Age : ranges from 23 to 82) and tumor size
(ts : 1mm ∼ 22mm) are considered as potential confounding factors.
We categorized age as young (age: ≤ 55) and old (age: > 55) and tumor size
as small (ts: ≤ 10mm) and large (ts: > 10mm), respectively as did in Senn et al
(2007). Distribution of baseline characteristics for these two covariates among the two
treatment groups and each stratum of age and tumor size combination are given in
Table 2.3.
First part of Table 2.3 suggests that age and tumor size are somewhat imbalanced
between the two treatment groups (59.4 yr v.s. 52.0 yr for mean age and 14.5mm v.s.
13.5mm for mean tumor size). Closer inspection of the second part of Table 2.3 reveals
that older patients with larger tumor size favor mastectomy procedure while younger
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patients with larger tumor size prefer lumpectomy procedure. This suggests that the
interaction of age and tumor size plays a role on the treatment assignment process.
Thus, we use the following logistic regression model to estimate the propensity score:
logit{PSi(= Pr(trti = 1 | (agei, tsi)))} = β0 + β1 ∗ agei + β2 ∗ tsi + β3 ∗ agei ∗ tsi
Analysis results using different analysis schemes are presented in Table 2.4.
First row of Table 2.4 presents the crude treatment effect estimate of 1.589 without
adjusting any confounding covariate. However, after adjusting the confounding factors,
the standard PS covariate adjustment, the proposed two-stage framework, and the mul-
tiple regression all end up with a sharply reduced treatment effect estimate as 0.793.
The treatment effect estimates using the PS stratification (with 4 strata) and IPW
scheme are even more sharply reduced to 0.013. All methods give us positive treat-
ment effect estimate indicating that the QoL for patients in the breast conservation
group is better than that of mastectomy group. However, this conclusion is not statis-
tically significant which can be easily checked from the corresponding 95% confidence
intervals. A further inspection of the standard error from each confounding adjustment
scheme also reveals that the standard error based on the proposed two-stage regression
framework is the smallest one among all methods compared.
2.6 Discussion
In this chapter, we proposed a new two-stage variance estimator for the treatment
effect estimate under the PS regression framework. We jointly modeled the response
and treatment assignment under the two-stage analysis framework which is different
from the standard PS regression scheme. We established the asymptotic result for the
treatment effect estimator based on the two-stage joint modeling scheme. An improved
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variance estimator was proposed based on the asymptotic result. As shown by our
simulations, the variance estimator from the standard PS regression model is biased in
general and this will lead to dramatically reduced power for hypothesis testings. This
variance estimator did not take into consideration the fact that the PSs used in the
second stage regression were estimated with errors. In contrast, the proposed two-stage
regression framework took this into consideration and provided an accurate variance
estimate.
Our simulation studies showed that both the standard PS regression and the pro-
posed two-stage methods can provide as efficient estimate as the multiple regression
can. We further demonstrated that the proposed variance estimator is robust under
various model misspecification settings. Accurate treatment effect estimate can still
be obtained using both the standard PS regression and the proposed two-stage frame-
work even when the model is misspecified while other methods including the multiple
regression may fail. These simulation results demonstrated the importance of using
the proposed variance estimator in practical comparative effectiveness research. The
proposed method has been implemented in a simple R function which can be freely
available from our website at http://www.bios.unc.edu/∼bzou/TwoStagePS/.
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Table 2.1: Simulation Results Under Settings (2.4) & (2.5)
# of covariates Monte Carlo Average 95% CI
p q Estimator Mean(αˆtrt) SD(αˆtrt) SE(αˆtrt) Coverage
Sample Size n=500
10 0 αˆtrt,S 0.501 0.273 0.301 94.7
αˆtrt,IPW 0.496 0.341 0.245 92.0
αˆtrt,LSE 0.498 0.115 0.114 94.2
αˆtrt,PSR 0.500 0.119 0.276 100.0
αˆtrt,P 0.497 0.119 0.117 94.6
10 10 αˆtrt,S 0.499 0.279 0.305 95.4
αˆtrt,IPW 0.487 0.319 0.250 92.6
αˆtrt,LSE 0.499 0.113 0.115 95.9
αˆtrt,PSR 0.499 0.115 0.279 100.0
αˆtrt,P 0.499 0.115 0.115 94.0
Sample Size n=5000
10 0 αˆtrt,S 0.506 0.070 0.103 99.9
αˆtrt,IPW 0.501 0.104 0.095 95.6
αˆtrt,LSE 0.500 0.036 0.036 94.5
αˆtrt,PSR 0.500 0.037 0.086 100.0
αˆtrt,P 0.500 0.037 0.036 93.7
10 10 αˆtrt,S 0.503 0.076 0.103 99.4
αˆtrt,IPW 0.499 0.103 0.093 93.5
αˆtrt,LSE 0.498 0.036 0.036 94.4
αˆtrt,PSR 0.498 0.037 0.086 100.0
αˆtrt,P 0.498 0.037 0.036 94.0
Note: p is the # of confounding covariates
q is the # of nuisance covariates
αˆtrt,S is PS stratification estimator with 5 equally divided strata
αˆtrt,IPW is IPW estimator
αˆtrt,LSE is the least square estimator
αˆtrt,PSR is PS regression estimator
αˆtrt,P is proposed estimator
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Table 2.2: Simulation Results Under Model Misspecification
Monte Carlo Average 95% CI
Estimator Mean(αˆtrt) SD(αˆtrt) SE(αˆtrt) Coverage
Quadratic term in treatment assignment but PS misfitted with linear term only
Sample Size n=500
αˆtrt,S 0.462 0.268 0.293 93.5
αˆtrt,IPW 0.491 0.305 0.244 91.7
αˆtrt,LSE 0.497 0.112 0.115 95.3
αˆtrt,PSR 0.497 0.114 0.276 100.0
αˆtrt,P 0.497 0.114 0.126 96.4
Sample Size n=5000
αˆtrt,S 0.460 0.075 0.103 99.1
αˆtrt,IPW 0.493 0.105 0.090 93.2
αˆtrt,LSE 0.499 0.035 0.036 95.4
αˆtrt,PSR 0.498 0.036 0.086 100.0
αˆtrt,P 0.498 0.036 0.039 96.6
Quadratic term in response but multiple regression misfitted with linear term only
Sample Size n=500
αˆtrt,S 0.449 0.374 0.341 92.3
αˆtrt,IPW 0.468 0.454 0.342 91.2
αˆtrt,LSE 0.449 0.239 0.247 95.2
αˆtrt,PSR 0.483 0.246 0.316 98.6
αˆtrt,P 0.483 0.246 0.252 95.1
Sample Size n=5000
αˆtrt,S 0.459 0.106 0.118 97.0
αˆtrt,IPW 0.501 0.147 0.134 95.8
αˆtrt,LSE 0.467 0.076 0.078 93.1
αˆtrt,PSR 0.501 0.077 0.098 99.0
αˆtrt,P 0.501 0.077 0.079 95.5
Note: see Table 2.1 for the table legends
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Table 2.3: Baseline Characteristics for German Breast Cancer Study Data
Mastectomy Lumpectomy
N Mean SD N Mean SD
Age (year) 167 59.4 10.4 479 52.0 11.5
Tumor Size (mm) 167 14.5 3.6 479 13.5 4.4
Mastectomy Lumpectomy
N Proportion N Proportion
Young (≤ 55 yr) Small (≤ 10 mm) 7 0.042 88 0.184
Young (≤ 55 yr) Large (> 10 mm) 49 0.293 206 0.430
Old (> 55 yr) Small (≤ 10 mm) 23 0.138 42 0.088
Old (> 55 yr) Large (> 10 mm) 88 0.527 143 0.298
Total 167 1.000 479 1.000
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Table 2.4: Analysis Results for German Breast Cancer Study Data
Estimator αˆtrt SE(αˆtrt) 95% CI
αˆtrt,Unadj 1.589 1.261 (-0.883,4.061)
αˆtrt,S 0.013 1.408 (-2.747,2.773)
αˆtrt,IPW 0.013 1.417 (-2.764,2.790)
αˆtrt,LSE 0.793 1.299 (-1.753,3.339)
αˆtrt,PSR 0.793 1.302 (-1.759,3.345)
αˆtrt,P 0.793 1.248 (-1.653,3.239)
Note: αˆtrt,Unadj is the estimator without adjusting any confounding factor
see Table 2.1 for the table legends
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Chapter 3
A Semi-Nonparametric PS Model for Clustered Observational Data
3.1 Introduction
In completely randomized clinical trials (RCT), treatments are randomly assigned.
Proper randomization procedures guarantee that there exists no systematic baseline
difference among subjects from different treatment groups. Therefore, RCT is regarded
as the scientific standard to establish the causal effect for a treatment and routinely used
in clinical trials for assessing drug efficacy. However, RCTs have their limitations (e.g.
Kramer and Shapiro 1984; Johnston et al. 2006) and can not always be conducted
in practice. With the ever readily availability of large clinical datasets, especially
the electronic medical record data, various efforts have been made to look into those
datasets in comparing the effectiveness of different treatments. Real world clinical data
offer a broader population spectrum as well as longer time-intervals than a typical
RCT data (e.g. Benson and Hartz 2000). They tend to reflect daily clinical practice
more closely and provide more clinically relevant information than RCTs (e.g. Yang
et al. 2010). The cost of using observational clinical data for comparative effectiveness
research (CER) is often much lower than that of using RCTs. Furthermore, large
medical record database provide an important resource to detect rare adverse events
that can not be detected during randomized controlled trials. Proper use of medical
record data for the comparative effectiveness research provides investigators an effective
way to compare various interventions for the inferiority, equivalence, or superiority (e.g.
Mitka 2010).
However, treatment allocation in practical clinical data tends to be not random.
Rather, the treatment assignment could be influenced by several factors that could
include patient’s, physician’s, and health care system’s factors. This nonrandomness
in treatment assignment could create imbalanced baseline covariates, i.e. confounding
variables, and result in severe biased treatment effect estimate if the confounding factors
are not appropriately adjusted. Several methods have been proposed to address the
confounding problems in observational studies, such as matching (e.g. Miettinen 1968),
stratification (e.g. Cochran 1968), the instrumental variable approach (e.g. Angrist et
al. 1996) and the propensity score method (e.g. Rosenbaum and Rubin 1983). Among
these methods, the propensity score (PS) approach is one of the leading ones commonly
used in practice.
For real world medical record data, the treatment assignment is clustered by physi-
cians, clinics and so on. They come from various sources that include insurance claim
data, hospital and clinic prescription records, etc. Generally, the particular treatment
a patient assigned depends on many factors which include but are not limited to: (1)
physician’s factors which include physician’s professional training, experience, practice
style and his/her determination on each patient’s reception to a particular treatment;
(2) patient’s factors which include patient’s prognostic status, his/her personal prefer-
ence on different treatments; and (3) system’s factors which include insurance policy,
hospital policy, etc. All these factors may reflect samples heterogeneity, for example,
in terms of patients’ health condition, social economical status which may affect both
treatment allocation process and disease outcomes.
In current statistical literature, there are a few methods dealing with the hetero-
geneity cluster effects in PS models based on a parametric mixed effects model where
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the cluster effects are assumed normally distributed (e.g. Thoemmes and West 2011).
This heterogeneity could be complex enough to be fully tracked, and existing simple
PS regression models may not be flexible enough to address the underlying hetero-
geneity. For electronic medical data, the normality assumption may not hold and the
heterogeneity caused by the incomplete measuring of the underlying dynamics in the
real world treatment assignment process could be too complex to be described by a
parametric model. Even worse, the heterogeneity is hidden and cannot be observed
directly, making model misspecification hard to be diagnosed. Such cluster effect mis-
specification could lead to invalid estimation of PS scores and subsequently result in
biased estimate of the treatment effect and erroneous conclusions.
To better capture the heterogeneity in treatment allocation process and reflect the
clustering feature of treatment assignment for real world medical data, we propose
a generalized mixed effect propensity score model to deal with the heterogeneity of
treatment allocations. We relax the normality assumption on the cluster effect in the
generalized mixed effects model with an unspecified cluster effect term. We refer the
proposed PS model as “SNP-PS” model (a.k.a. semi-nonparametric PS model).
The proposed SNP-PS model deals with the heterogeneity of treatment allocation in
a robust fashion without the parametric assumptions on the random effects. It jointly
models the heterogeneity structure in treatment allocation process and the outcome
under non-randomized designs. We establish the asymptotic results for the treatment
effect estimator under semi-nonparametric propensity score regression framework that
allows us to develop an improved variance estimator for the treatment effect estimate.
Simulation results reveal that our proposed variance estimator for the treatment ef-
fect estimate is unbiased while the commonly used default variance estimator by PS
regression method is biased. A new and efficient adaptive integration algorithm is de-
veloped to avoid the potential large Monte Carlo errors in assessing the non-closed form
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log-likelihood function of SNP-PS model for parameters estimation.
The rest of the chapter is arranged as follows. We present the mathematical de-
scription of the proposed SNP-PS approach in Section 2. Detailed procedures for the
parameter estimates and propensity score estimations are given in Section 3. Asymp-
totic results for the proposed SNP-PS estimator are outlined in Section 4. We present
the simulation studies under different heterogeneity structures in Section 5. We demon-
strate the real application of the proposed SNP-PS method in Section 6. Final remarks
are given in Section 7. In Appendix II, we present the mathematical derivation for
the asymptotic results of SNP-PS estimator. Furthermore, since the sampling from
SNP density is not readily available in the existing statistical software package, we also
provide the sampling scheme from SNP density in Appendix III.
3.2 Semi-Nonparametric PS Model
Before introducing our semi-nonparametric propensity score model, we first briefly
describe the standard propensity score model below.
3.2.1 Standard PS Model
Let yi, trti and xi represent the outcome, treatment assignment, and observed
baseline covariates of subject i (i = 1, . . . , n), respectively. Furthermore, yis are inde-
pendently identically distributed (iid).
The validity of the PS approach was established by Rosenbaum and Rubin (1983)
who showed that under the following conditions,
(y(1), y(0)) ⊥ trt|x and 0 < Pr(trt = 1|x) < 1, (3.1)
the measured baseline covariates will be similar between the treated and untreated
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subjects with similar propensity scores (PS ≡ Pr(trt = 1|x)). Here x are the observed
covariates. y(1) and y(0) are the potential outcomes of a particular unit if it had been
assigned to the treated and untreated group, respectively. They are never observed
simultaneously in reality. Their relationship with the observed outcome y and the
treatment assignment trt (1 and 0 for treated and untreated assignment, respectively)
can be expressed as y = trt× y(1) + (1− trt)× y(0). The first condition in (3.1) says
that the treatment assignment is independent of the potential outcomes conditional on
the observed baseline covariates. Based on PS, the treatment effect can be estimated
via matching (e.g. Tanasescu et al. 2002; Dehejia and Wahba 2002), stratification (e.g.
Rosenbaum and Rubin 1984; He and McDermott 2012), inverse-probability-weighting
(IPW) (e.g. Do and Finch 2008), or covariate adjustment (e.g. Koch et al. 2008; Shaw
et al. 2008). In practice, the propensity score is not observed and the following logistic
regression model:
logit(Pr(trt = 1 | x)) = β0 + xβ, (3.2)
is often used to estimate the PS as the following:
P̂S = exp(βˆ0 + xβˆ)/[1 + exp(βˆ0 + xβˆ)].
where βˆ0 and βˆ are parameters estimates of β0 and β in model (3.2).
In the above standard PS model, the treatment assignment heterogeneity is not
taken into consideration. As described earlier, in practical medical record data, the
treatments are non-randomly assigned and clustered, for example, by physician, and/or
clinics, etc. To capture the complex heterogeneity structures of treatment assignment
process in practical medical record data, we propose the following semi-nonparametric
propensity score model.
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3.2.2 First Stage Semi-Nonparametric PS Model
Let yij, trtij and xij represent the outcome, the treatment assignment, and the
observed covariates of subject j nested in cluster i (j = 1, . . . , ni; i = 1, . . . , n), respec-
tively.
We extend the standard PS model (3.2) to the following mixed effects logistic re-
gression model:
logit(Pr(trtij = 1 | xij)) = β0 + xijβ + ηi (3.3)
where ηi is a random cluster effect. Instead of restricting η to follow a normal distri-
bution, we assume that it follows an unknown smooth density function f(η).
Estimation of f(η), can be done through various density estimation methods (e.g.
Rosenblatt 1956; Parzen 1962; Wahba 1975; Scott 1979; Sheather and Jones 1991;
Botev et al. 2010). We adopt Gallant and Nychka (1987) method that uses a truncated
Hermite series multiplied by a normal density to estimate f(η).
SNP representation: Specifically, we approximate f(η) by the following trun-
cated K + 1 terms of Hermite polynomial multiplied by a normal density (e.g. Gallant
and Nychka 1987; Davidian and Gallant 1993; Zhang and Davidian 2001; Chen et al.
2002) as shown below:
f(η;ψ, µ, σ2) ≈ fK(η;ψ, µ, σ2) = H2K(
η − µ
σ
;ψ)φ(η;µ, σ2)
where φ(η;µ, σ2) is the density function of the normal distribution with mean µ and vari-
ance σ2. HK(z;ψ) is a Hermite polynomial with K+1 terms. In practice, most data in-
cluding skewed, fat, and t-like tail densities can be approximated well by fK(η;ψ, µ, σ
2)
with K ≤ 2 (Gallant and Nychka 1987). The first three Hermite polynomials are given
below (details on higher order Hermite polynomials can be found in Gallant and Nychka
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1987).
HK(z;ψ) =

1 if K = 0
cos(ψ) + zsin(ψ) if K = 1
(cos(ψ1)− sin(ψ1)sin(ψ2)√2 ) + zsin(ψ1)cos(ψ2) + z2
sin(ψ1)sin(ψ2)√
2
if K = 2
where parameters (ψ, ψ1, ψ2) ∈ (−pi2 , pi2 ]. This approximation provides a fully parametric
representation for the completely nonparametric specifications and is termed by Gallant
and Nychka (1987) as semi-nonparametric (SNP) representation. Let ω = (µ, σ2) (for
K = 0), or ω = (ψ, µ, σ2) (for K = 1) or ω = (ψ1, ψ2, µ, σ
2) (for K = 2) be the set of
parameters used for characterizing the density of η under SNP representation. When
K = 0, fK(η;ω) reduces to a normal distribution.
SNP-PS log-likelihood: With the use of SNP representation for the density
function, the log-likelihood of the semi-nonparametric logistic regression model (3.3)
can be written as:
l(β,ω) =
n∑
i=1
li(β,ω) =
n∑
i=1
log
[∫ ∞
−∞
ni∏
j=1
f(trtij | xij, ηi;β)f(ηi;ω)dηi
]
(3.4)
where f(trt | x, η;β) is the logistic density function given by the following:
f(trt | x, η;β) = exp(trt ∗ [xβ + η])
1 + exp(xβ + η)
Note that in the proposed SNP-PS model (3.3), we do not restrict the cluster effect
term η to have mean 0. Thus, parameters β0 and E(η) cann’t be separated and only
β0 + E(η) is estimable. For model identifiability purpose, we set β0 = 0. No analytic
closed form for this log-likelihood is available. To get the maximum likelihood estimate
(MLE) of the parameters θ = (β,ω), we adopt EM algorithm (Dempster et al. 1977)
based on an adaptive integration mechanism to evaluate the non-analytic closed form
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log-likelihood function (detailed in Section 3).
3.2.3 Second Stage Semi-Nonparametric PS Regression Model
After the parameters of SNP-PS model (3.3) are estimated, we estimate the propen-
sity score for each subject used for the subsequent treatment effect estimate. Specifi-
cally, we predict the cluster effect of cluster i, i.e. ηi as:
ηˆi = Eηi|{trt ij }j (ηi | {trt ij}j ; θˆ) =
∫ ∞
−∞
ηi f (ηi | {trt ij}j ; θˆ)dηi
Based on it, we get the estimated propensity score of subject j in cluster i as:
P̂Sij = Pr(trtij = 1 | xij; θˆ) = exp(xijβˆ + ηˆi)
1 + exp(xijβˆ + ηˆi)
(3.5)
With the propensity scores estimated (i.e. P̂Sij), we estimate the treatment effect via
the following regression model:
yij = α0 + αtrttrtij + α1P̂Sij + ij (3.6)
with ij ∼ N(0, σ2) being the random measurement error.
3.3 An EM Procedure for Parameter Estimation
To obtain the estimation of the parameters θ = (β,ω) in (3.4), we adopt EM
algorithm by treating the cluster effect η as missing, resulting in the full data as (trt,
x, η). The full data likelihood is then given by:
f({trt ij}j , {xij}j , ηi ;θ) = f({trt ij}j , {xij}j | ηi ;β)f (ηi ;ω)
= [
ni∏
j=1
f(trtij | xij, ηi;β)]f(ηi;ω)
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where f(ηi;ω) is the unspecified heterogeneity density that can be represented via
semi-nonparametric method given in the previous section. This leads to the full data
log-likelihood given below:
l(θ) =
n∑
i=1
li(θ) =
n∑
i=1
{[
ni∑
j=1
log f(trtij | xij, ηi;β)] + log f(ηi;ω)}.
E-step: Along with the above full data log-likelihood, the (r+ 1)th E-step of EM
algorithm for SNP-PS is to evaluate the following conditional expectation of full data
log-likelihood:
Q(θ | θ(r)) = Eη|trt(l(θ)) =
n∑
i=1
Eηi|{trtij}j (li(θ))
=
n∑
i=1
∫ ∞
−∞
{[
ni∑
j=1
log f(trtij | xij , ηi;β)] + log f(ηi;ω)} ×
f(ηi | {trt ij }j , {xij }j ;θ(r))dηi
where θ(r) is the estimates from the (r)th M-step or the initial values of the parameters.
The evaluation of the above conditional expectation is not trivial since there is no
analytic closed form. Chen et al. (2002) has proposed a double-rejection Monte Carlo
sampling scheme to replace the integration over the cluster effect by the summation
over the samples from the conditional density f(ηi | {trt ij}j , {xij}j ;θ(r)). However, the
double-rejection sampling approach is not efficient for the SNP-PS model due to its
potentially large Monte Carlo error and low acceptance rate for binary data. Alterna-
tively, we adopt the numerical integration scheme. By Bayes’ law, we can rewrite the
conditional density f(ηi | {trt ij}j , {xij}j ; θ(r)) as the following:
f(ηi | {trt ij}j , {xij}j ;θ(r)) =
[
∏ni
j=1 f (trtij | xij , ηi ;β(r))]f (ηi ;ω(r))∫∞
−∞[
∏ni
j=1 f (trtij | xij , ηi ;β(r))]f (ηi ;ω(r))dηi
.
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Based on this new expression of f(ηi | {trt ij}j , {xij}j ;θ(r)), we can obtain the numer-
ical evaluation for quantity Q(θ | θ(r)) since the analytic expression for [∏nij=1 f(trtij |
xij, ηi;β
(r))]f(ηi;ω
(r)) is available with a given Hermite expansion term K.
M-step: Once Q(θ | θ(r)) is estimated, in M-step, we maximize it to obtain
the (r + 1)th step parameter estimate of θ = (β,ω) = (β, ψ, µ, σ2). Notice that
the parameters related to the fixed effects part, i.e. β, and the cluster effects part,
i.e. ψ, µ, σ2, can be separated and optimized separately. That is, we perform the
optimization on the following two functions evaluated in the E-step separately:
QF (β | θ(r)) =
n∑
i=1
∫ ∞
−∞
[
ni∑
j=1
log f(trtij | xij, ηi;β)]f(ηi | {trt ij}j , {xij}j ;θ(r))dηi
QR(ω | θ(r)) =
n∑
i=1
∫ ∞
−∞
[logPK(zi;ω) + log φ(ηi;µ, σ
2)]f(ηi | {trt ij}j , {xij}j ;θ(r))dηi
where zi =
ηi−µ
σ
and PK(zi;ω) = H
2
K(zi;ω).
Specifically, we optimize QF (β | θ(r)) using the L-BFGS-B algorithm (Byrd et al.
1995). The L-BFGS-B algorithm is an extension of the L-BFGS algorithm to handle
simple bounds on the model (Zhu et al. 1997). The L-BFGS algorithm is an efficient
algorithm and particularly suited for optimization problems with a large number of
variables. L-BFGS-B uses the ideas from the trust region methods while keeping the
L-BFGS update of the Hessian and line search algorithms.
However, there exists singularity for the derivatives of the cluster effect with respect
to ω when K > 0. Therefore, we use Nelder-Mead algorithm (Nelder and Mead 1965)
to maximize QR(ω | θ(r)). Nelder-Mead algorithm uses only function values and works
reasonably well for non-differentiable functions.
In practice, the Hermit expansion term K for the SNP representation is unknown
and needs to be determined. Commonly used model selection criteria, for example,
AIC (Akaike 1974) or BIC (Schwarz 1978) can be used for this purpose (Zhang and
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Davidian 2001). Specifically, we select the model that minimizes − logL(θˆ; trt,x)+cK ,
where
− logL(θˆ; trt,x) = −
n∑
i=1
{
∫ ∞
−∞
[
ni∏
j=1
f(trtij | xij, ηi; βˆ)]f(ηi; ωˆ)dηi},
and cK = DK or
1
2
(logN)DK (for AIC and BIC, respectively) is a penalization term
on the number of parameters used in the model with DK denoting the dimension of θ
and N =
∑n
i=1 ni representing the total number of subjects in the dataset.
In summary, the following procedure summarizes the proposed SNP-PS regression
model to obtain the treatment effect estimate for the clustered data:
Step 1: Fit a set of SNP-PS models with different Hermite expansion terms (e.g.
K = 0, 1, and 2) via the above EM algorithm.
Step 2: Use the model selection criteria AIC or BIC to select the optimum SNP-PS
model and estimate the PS for the selected model.
Step 3: Plug in the estimated PS scores into PS regression model (3.6) to obtain the
treatment effect estimate αˆtrt.
To obtain the valid variance estimator for αˆtrt, we first establish the asymptotic
results for αˆtrt in the below section. From which we propose an improved variance
estimator for the treatment effect estimate under SNP-PS regression framework.
3.4 Asymptotic Results
Before presenting the details of the theoretical results for SNP-PS model, we first
introduce the following assumptions:
For samples within each cluster, (y(1), y(0)) ⊥ trt|x and 0 < Pr(trt = 1|x) < 1
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These assumptions are similar to the strongly ignorable treatment assignment assump-
tions of Rosenbaum and Rubin (1983). The strongly ignorable assumptions in Rosen-
baum and Rubin (1983) are conditional on x for all samples while ours are conditional
on x restricted for samples within each cluster and refered as the modified strongly ig-
norable treatment assignment assumption. In order words, the cluster effect is treated
as an unobserved confounding covariate.
Following the similar argument of Rosenbaum and Rubin (1983), under the above
modified strongly ignorable treatment assignment assumptions, αˆtrt in model (3.6) can
be shown to approximate the true treatment effect well.
However, the default variance estimate of αˆtrt obtained directly from model (3.6),
on the other hand, is a biased estimate for the (unknown true) variance of αˆtrt since
it ignores the fact that the PS used in (3.6) are estimated quantities with random
errors instead of the observed covariates. It turns out that the PS regression can
be viewed as a two-stage procedure that commonly used in a wide class of empirical
applications where unobserved regressors, such as expectations, are estimated from
auxiliary statistical models. It is well-known that the estimated standard errors and
related test statistics directly from the second-step regression are incorrect (Murphy and
Topel 1985). With the joint modeling scheme, under the SNP-PS regression framework,
we develop the asymptotic result for αˆtrt as described below. Based on it, we propose
a variance estimator with good finite sample performance as shown in our subsequent
simulation studies.
First, we write the log-likelihood for the first stage SNP-PS model (3.3) as the
following:
l1(θ1) =
n∑
i=1
l1i(θ1) =
n∑
i=1
log
{∫ ∞
−∞
ni∏
j=1
f(trtij | xij, ηi;β)f(ηi;ω)dηi
}
with θ1 = (β,ω).
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For the second stage analysis, we have
l2(θ1,θ2) =
n∑
i=1
l2i(θ1,θ2) ≡
n∑
i=1
log f({yij}j; {trt ij}j | {PSij}j)
=
n∑
i=1
log {f({yij}j | {PSij}j; {trt ij}j)f({trt ij}j | {PSij}j)}
=
n∑
i=1
log {f({yij}j | {PSij}j; {trt ij}j)}+
n∑
i=1
log {f({trt ij}j | {PSij}j)}
with θ2 = (α0, αtrt, α1, σ
2)T .
Given the (unknown) true PS score PSij of each sample and the strong ignorable
assumptions, the above log-likelihood can be approximated as
l2i(θ1,θ2) = l2i,a(θ1,θ2) + l2i,b(θ1)
where l2i,a(θ1,θ2) = −ni2 log(2pi)− ni2 log(σ2)− 12σ2
∑ni
j=1(yij −α0−αtrttrtij −α1PSij)2
and l2i,b(θ1) =
∑ni
j=1 log
(
PS
trtij
ij (1− PSij)1−trtij
)
In PS regression model, the PS scores are first estimated via model (3.5), then the
estimated PS scores are plugged into model (3.6) to obtain αˆtrt, the parameter of the
primary interest. Note that when PSijs are replaced by P̂Sijs, maximizing the likeli-
hood l2(θ1,θ2) reduces to maximizing the log-likelihood of the simple linear regression
model (3.6) for the purpose of the treatment effect estimates. The term l2i,b(θ1) in the
above expression for l2i(θ1,θ2) plays a critical role for the variance estimation. Ignoring
this term will lead to the biased variance estimate for the parameter estimators. With
these preparations, under some regularity conditions, we have the following asymptotic
result for αˆtrt within the SNP-PS regression framework:
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Theorem 3.4.1. (Asymptoticness) The treatment effect estimator αˆtrt is asymptoti-
cally normally distributed with:
√
n(αˆtrt − α∗trt)→ N(0, σ222)
where σ222 is the second diagonal element of the covariance matrix Σ = V2+V2[CV1C
T−
RV1C
T −CV1RT ]V2 with V −11 = E
{(
∂l1
∂θ1
)(
∂l1
∂θT1
)}
, V −12 = E
{(
∂l2
∂θ2
)(
∂l2
∂θT2
)}
,
C = E
{(
∂l2
∂θ2
)(
∂l2
∂θT1
)}
, and R = E
{(
∂l2
∂θ2
)(
∂l1
∂θT1
)}
. Under the strongly ignorable
condition (3.7) and the linearity assumption in COROLLARY 4.3 of Rosenbaum and
Rubin (1983), α∗trt can be replaced by αtrt, the true marginal treatment effect.
The detailed proof is outlined in Appendix II. The above theorem provides us a basis
for a modified variance estimator. To estimate the covariance matrix Σ, we propose a
sample estimate of Σ as follows:
Σˆ = Vˆ 2 + Vˆ 2[CˆVˆ 1Cˆ
T − RˆVˆ 1CˆT − CˆVˆ 1RˆT ]Vˆ 2
where Vˆ
−1
1 =
1
n
∑n
i=1
∂l1,i
∂θ1
∂l1,i
∂θT1
| ˆθ1 , Vˆ
−1
2 =
1
n
∑n
i=1
∂l2,i
∂θ2
∂l2,i
∂θT2
| ˆθ1, ˆθ2 , Cˆ =
1
n
∑n
i=1
∂l2,i
∂θ2
∂l2,i
∂θT1
| ˆθ1, ˆθ2 and Rˆ =
1
n
∑n
i=1
∂l2,i
∂θ2
∂l1,i
∂θT1
| ˆθ1, ˆθ2 , respectively. Matrix Σˆ provides
a good estimate to Σ as can be demonstrated by the simulation studies below.
3.5 Simulation Studies
We evaluate the finite sample performance of the proposed SNP-PS estimator by
conducting extensive Monte Carlo simulation studies under various heterogeneity struc-
tures. The simulation studies are conducted according to the following treatment as-
signment mechanism:
logit(PSij = Pr(trtij = 1 | xij)) = β1x1,ij + β2x2,ij + ηi, (3.7)
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where j = 1, · · · , ni indexes subjects nested in cluster i, (β1, β2) = (−0.5, 0.15), x1,ij ∼
Bern(0.5), and x2,ij ∼ N(0, 1). We let the cluster effect η to follow the following
distribution:
η ∼ fK(η;ψ, µ, σ2) = f1(η;−pi
3
, 0.3, 1.5).
This is a SNP density with Hermite expansion terms truncated at K=1 corresponding
to a non-normal distribution (i.e. bio-mode distribution).
The responses are generated based on the following data generating process:
yij = α0 + αtrttrtij + αx1x1,ij + αx2x2,ij + bξi + ij, (3.8)
where (α0, αtrt, αx1 , αx2) = (0.3, 0.5, 1.5, 0.5). ij ∼ N(0, 1.0) is independent of trtij,
xij, and ξi. Distribution of ξi will be discussed in next paragraph. The overall cluster
effect on the response is set as b = 0 and −0.3, respectively. For b = 0, it corresponds
to the scenario of no cluster effect on the response.
To mimic the real world data, we also generate two additional covariates x3 ∼
Unif(−1, 1) and x4 ∼ Exp(1) which do not affect the treatment assignment and
the response. We refer these covariates as nuisance variables. We include both the
confounding covariates and nuisance variables in the SNP-PS model to estimate the
propensity scores.
In addition to the above various configurations for the parameter values, we also
investigate the performance of the proposed estimator αˆtrt under different cluster effects
settings for ξ in the response with respect to the cluster effects η in the treatment
assignment process including no cluster effects, i.e. b = 0 (Case 1), ξ = η (Case 2), and
ξ = 0.65 ∗ η + 0.35 ∗N(0, 1) (Case 3).
Under each setting, we compare the proposed SNP-PS regression method with three
other methods. The first method is the unadjusted model where the treatment effect
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estimate is obtained by comparing the differences between the two treatment groups
without adjusting any other confounding factors. The other two methods are PS re-
gression based methods where the propensity scores are estimated using the following
logistic regression models:
logit(PSij = Pr(trtij = 1 | xij)) = γ0 + γ1x1,ij + γ2x2,ij + γ3x3,ij + γ4x4,ij, (3.9)
where the cluster effect is completely ignored in the treatment assignment process and
we refer this method as Naive-PS method.
Instead of ignoring the cluster effect, a normal cluster effect is taken into consider-
ation in the following mixed effects logistic regression model:
logit(PSij = Pr(trtij = 1 | xij)) = γ0 + γ1x1,ij + γ2x2,ij + γ3x3,ij + γ4x4,ij + ζi, (3.10)
where the mixed effects logistic regression model with a normally distributed cluster
effects ζi ∼ N(0, σ2ζ ) is used to estimate the PS. We refer this PS estimation method
as Normal-PS method.
For all methods compared, the treatment effect estimate αˆtrt is obtained from the
PS regression model (3.6) by plugging in the estimated PS. We first start with sample
size of 1000 and the cluster cell size fixed at 5. Results for this simulation setting
are presented in Table 3.1. We then increase the sample size to 5000 and results for
this setting are given in Table 3.2. Column “Mean(αˆtrt)” represents the average of
the estimated treatment effect, αˆtrt. Column “Monte Carlo SD(αˆtrt)” represents the
Monte Carlo standard deviation of αˆtrt based on 500 simulations which can be viewed
as the true error of the treatment effect estimate. Column “Average ŜED(αˆtrt)” is the
average of the default standard errors of αˆtrt output from the second stage PS regression
model (3.6). Column “Average ŜEP (αˆtrt)” is the average of the standard errors of αˆtrt
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calculated based on our proposed variance estimator, i.e. ŜEP (αˆtrt) =
√
Σˆ[2,2], with
Σˆ[2,2] being the second diagonal element of covariance matrix Σˆ given in Theorem 3.4.1.
Comparing Tables 3.1 and 3.2, we notice that the unadjusted model always produces
severely biased treatment effect estimates in all simulation settings. Naive-PS regression
approach which ignores the treatment assignment heterogeneity also produces severely
biased treatment effect estimates when there exists the cluster effects in the response
(Case 2 & 3). Naive-PS is only acceptable when there is no cluster effects in the
response (Case 1). A further examining Tables 3.1 and 3.2 also show that the normal-
PS estimator also exhibited consistent bias in estimating αtrt. The proposed SNP-PS
estimator is the only estimator that unbiasedly estimates αtrt. This demonstrated the
robustness of the proposed SNP-PS model in both the point estimate and variance
estimate when data is not following a normal heterogeneity distribution.
Tables 3.1 and 3.2 also show that the default standard error ŜED(αˆtrt) output
directly from the PS regression model is biased in all simulation settings no matter
which propensity score regression scheme is used. In contrast, the proposed variance
estimator ŜEP (αˆtrt) performs very well in all situations considered regardless if normal
or SNP-PS regression approach is used.
To investigate the efficiency of SNP-PS regression in the scenario of normal cluster
effect in the treatment assignment process, we conduct another set of simulation by
setting the cluster effect η in the treatment allocation model (3.7) to follow N(−0.2, 1)
and the setting of the cluster effect ξ in response model (3.8) for Case 3 is set as
ξ = 0.65 ∗ η + 0.35 ∗N(0, 1). Results for this setting of sample size 5000 are presented
in Table 3.3.
Similar observations can be obtained from Table 3.3: there exists a large difference
between the treatment effect estimate based on the unadjusted model and the true
effect size. Naive-PS regression model results in biased treatment effect estimates in
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the situations of clustered data. Normal-PS and SNP-PS regression models provide
unbiased treatment effect estimates regardless whether there are the cluster effects in
response or not. Again, the proposed variance estimator provides very accurate variance
estimates in all simulation settings. Also, the SNP-PS regression estimator and the
normal PS regression estimator have identical efficiency in all simulation settings. This
is expected since SNP-PS model includes the normal-PS model as a special case. That
is the proposed SNP-PS method won’t lose efficiency when the true model is normal.
The price to pay is the extra computational workload.
In summary, the proposed SNP-PS regression model provides unbiased point esti-
mate for αtrt regardless if there is cluster effect in response, or if heterogeneity in cluster
effect is normally distributed. Furthermore, the proposed variance estimator provides
accurate variance estimate for the variance of αˆtrt under the SNP-PS regression frame-
work in all simulation settings. In contrast, the default variance estimator provides
biased variance estimate.
3.6 Real Data Analysis
To demonstrate the practical use of the proposed SNP-PS regression model, we
applied it to a multi-center breast cancer study conducted by German Breast Can-
cer Study Group (Rauschecker et al. 1995). The study originally was intended as
a randomized trial but had to be changed to an observational study due to the low
randomization rate. The primary objective of this study was to compare the simple
mastectomy (trt = 0) versus lumpectomy (BC, breast conservation, trt = 1) on the
effect of quality of life (QoL) for 1036 breast cancer patients. The primary outcome
was the performance status 9 months after surgery, which is scored between 0 and
100 based on the 25 QoL questionnaire responses, with higher scores reflecting better
QoL. Covariates other than the therapies (i.e. mastectomy vs. lumpectomy) including
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patient age (ranges from 23 to 82) and tumor size (1mm ∼ 22mm) were considered as
the potential confounding factors.
Our analysis was based on a sub-data set of this study from “nonrandom” R package
with 646 patients and 63 clinics. We categorized age as young (age: ≤ 55) and old (age:
> 55) and tumor size as small (ts: ≤ 10mm) and large (ts: > 10mm), respectively
as done by Senn et al. (2007). Distribution of baseline characteristics for these two
covariates among the two treatment groups and each stratum of age and tumor size
combination are presented in Table 3.4.
First part of Table 3.4 suggests that both age and tumor size are somewhat imbal-
anced between the two treatment groups. The mean age for the two groups are 59.4
yr and 52.0 yr with the corresponding standard deviation 10.4 and 11.5, respectively.
The mean tumor size for the two groups are 14.5 mm and 13.5mm with standard devi-
ation of 3.6 and 4.4. Taking a closer inspection of the second part of Table 3.4 reveals
that older patients with larger tumor size favor mastectomy procedure while younger
patients with larger tumor size prefer lumpectomy procedure. This suggests that the
interaction of age and tumor size plays a role on the treatment assignment process.
Furthermore, our likelihood ratio test showed that the cluster effect due to the clinic
is significant (p < 10−10) in determining the treatment assignment. Based on it, we
include age, ts, and their interactions as the observed confounding covariates in the
corresponding logistic regression models considered. Analysis results based on different
analysis schemes are summarized in Table 3.5.
An evident observation from Table 3.5 is that the treatment effect estimate based on
the unadjusted model is much larger than that based on all other methods compared.
However, after adjusting the confounding factors via the propensity score regression
method based on different versions of propensity score models, the treatment effect
estimates are appreciably reduced. Different estimation schemes give us quite different
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but all positive treatment effect estimates. The positive number indicates that the
QoL for the breast conservation patients is on average better than that of mastectomy
patients. However, this conclusion is not statistically significant. This can be confirmed
by checking the corresponding 95% confidence interval. Per our model selection criteria,
SNP-PS regression model with Hermite expansion term K = 1 best fit this multicenter
observational dataset and results based on it should be used.
Overall, based on the data collected for this multi-center study, there exists no
statistically significant difference on the QoLs of breast cancer patients between the
two treatment procedures after adjusting the patient age, tumor size, their interaction
and the cluster effect.
3.7 Discussions
In this chapter, we proposed a semi-nonparametric propensity score model to deal
with the treatment allocation heterogeneity that is commonly observed in real world
medical data. The proposed SNP-PS model is robust to the parametric assumption
for the heterogeneity distribution without making any specific parametric distribution
assumption. Instead, a truncated Hermite polynomial along with the normal density
is used to approximate the unspecified heterogeneity density. The Hermite expansion
term can be determined via the frequently used model selection criteria, i.e. AIC or
BIC etc. Numerically, we propose an adaptive quadrature integration algorithm to
assess the non-closed form log-likelihood function for the proposed SNP-PS parameter
estimates to avoid the large Monte Carlo errors of existing sampling based methods
and reduce the computational workload. Furthermore, the biased variance estimate for
the commonly used PS regression model is identified and corrected by our proposed
robust variance estimator. Our proposed variance estimator for the SNP-PS regression
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model is critical in practice, as it will allow us to conduct valid statistical inference
and lead to correct scientific conclusions that could be erroneous if the default variance
estimator was used.
In addition to the propensity score estimation method described in equation (3.5),
we have also studied another estimation method, the posterior mode method. In this
method, P̂Sij =
exp(xij βˆ+ηˆMi)
1+exp(xij βˆ+ηˆMi)
with ηˆMi = arg maxηi li(ηi | trti,xi; βˆ). This prediction
method is the default one in the generalized linear mixed model packages in both SAS
and R. However, this prediction does not perform nearly as good as the empirical
Bayesian based prediction method (3.5).
The proposed SNP-PS for treatment allocation heterogeneity and their perfor-
mances are all based on continuous responses. In real applications, there exists other
type of responses commonly observed in CER studies, such as the binary (e.g. cure vs
non-cure) events, and time to event (e.g. cure or death) data. Extending the proposed
SNP-PS model to these data types under heterogeneous treatment assignment deserves
further research and investigations. For example, longitudinal data where patients are
followed up over years of medical interventions frequently exist in real world medical
data. Such longitudinal resources would pose additional challenges in dealing with the
time-dependent confounding.
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Table 3.1: Non-Normal Cluster Effects in Treatment Allocation (Sample Size 1000)
Average Monte Carlo Average Average
Method αˆtrt SD(αˆtrt) ŜED(αˆtrt) ŜEP (αˆtrt)
Case 1: ξ = 0
Unadjusted 0.426 0.095 0.093
Naive-PS 0.498 0.073 0.087 0.073
Normal-PS 0.539 0.107 0.127 0.100
SNP-PS 0.524 0.098 0.124 0.096
Case 2: ξ = η
Unadjusted -0.165 0.108 0.096
Naive-PS -0.098 0.093 0.092 0.078
Normal-PS 0.536 0.106 0.128 0.105
SNP-PS 0.503 0.098 0.125 0.102
Case 3: ξ = 0.65 ∗ η + 0.35 ∗N(0, 1)
Unadjusted 0.041 0.108 0.096
Naive-PS 0.110 0.093 0.092 0.078
Normal-PS 0.537 0.106 0.131 0.107
SNP-PS 0.509 0.098 0.127 0.103
Note: Results are based on 500 simulations
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Table 3.2: Non-Normal Cluster Effects in Treatment Allocation (Sample Size 5000)
Average Monte Carlo Average Average
Method αˆtrt SD(αˆtrt) ŜED(αˆtrt) ŜEP (αˆtrt)
Case 1: ξ = 0
Unadjusted 0.426 0.041 0.041
Naive-PS 0.502 0.030 0.040 0.031
Normal-PS 0.546 0.048 0.057 0.044
SNP-PS 0.529 0.043 0.055 0.042
Case 2: ξ = η
Unadjusted -0.168 0.050 0.043
Naive-PS -0.097 0.041 0.041 0.033
Normal-PS 0.545 0.047 0.057 0.046
SNP-PS 0.508 0.043 0.055 0.044
Case 3: ξ = 0.65 ∗ η + 0.35 ∗N(0, 1)
Unadjusted 0.040 0.047 0.043
Naive-PS 0.113 0.038 0.042 0.033
Normal-PS 0.546 0.047 0.058 0.047
SNP-PS 0.515 0.044 0.057 0.045
Note: Results are based on 500 simulations
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Table 3.3: Normal Cluster Effects in Treatment Allocation (Sample Size 5000)
Average Monte Carlo Average Average
Method αˆtrt SD(αˆtrt) ŜED(αˆtrt) ŜEP (αˆtrt)
Case 1: ξ = 0
Unadjusted 0.424 0.037 0.040
Naive-PS 0.501 0.030 0.039 0.030
Normal-PS 0.505 0.037 0.049 0.037
SNP-PS 0.505 0.037 0.049 0.037
Case 2: ξ = η
Unadjusted -0.108 0.069 0.042
Naive-PS -0.036 0.068 0.041 0.033
Normal-PS 0.502 0.037 0.049 0.039
SNP-PS 0.502 0.037 0.049 0.039
Case 3: ξ = 0.65 ∗ η + 0.35 ∗N(0, 1)
Unadjusted 0.078 0.067 0.042
Naive-PS 0.152 0.065 0.041 0.033
Normal-PS 0.503 0.037 0.050 0.040
SNP-PS 0.503 0.037 0.050 0.040
Note: Results are based on 500 simulations
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Table 3.4: Baseline Distribution for German Breast Cancer Study Data
Mastectomy Lumpectomy
N Mean SD N Mean SD
Age (year) 167 59.4 10.4 479 52.0 11.5
Tumor Size (mm) 167 14.5 3.6 479 13.5 4.4
Mastectomy Lumpectomy
N Proportion N Proportion
Young (≤ 55 yr) Small (≤ 10 mm) 7 0.042 88 0.184
Young (≤ 55 yr) Large (> 10 mm) 49 0.293 206 0.430
Old (> 55 yr) Small (≤ 10 mm) 23 0.138 42 0.088
Old (> 55 yr) Large (> 10 mm) 88 0.527 143 0.298
Total 167 1.000 479 1.000
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Table 3.5: Analysis of German Breast Cancer Study Data with Cluster Effects
Method αˆtrt SE(αˆtrt) 95% CI
Unadjusted 1.589 1.261 (-0.883,4.061)
Naive-PS 0.793 1.248 (-1.653,3.239)
Normal-PS 0.560 1.645 (-2.664,3.784)
SNP-PS 0.715 1.636 (-2.492,3.922)
Note: model selection criteria indicates K = 1 for SNP-PS best fit this dataset
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Chapter 4
A Flexible Mixed Effects PS Model for Clustered Data
4.1 Introduction
With the ever readily availability of large clinical datasets, especially the electronic
medical record data, various efforts have been made to look into those datasets in com-
paring the effectiveness of different treatments. Real world clinical data offer a broader
population spectrum as well as longer time-intervals than a typical RCT data (e.g.
Benson and Hartz 2000). They tend to reflect daily clinical practice more closely and
provide more clinically relevant information than RCTs (e.g. Yang et al. 2010). The
cost of collecting observational clinical data for conducting comparative effectiveness
research (CER) is often much lower than that of conducting RCTs. Proper use of
medical record data for the comparative effectiveness research provides investigators
an effective way to compare various interventions for the inferiority, equivalence, or
superiority (e.g. Mitka 2010).
As a kind of observational data, a key feature of medical record data is that the
treatment allocation is not random. Rather, the treatment assignment could be in-
fluenced by many factors related to patients, physicians, and health care systems etc.
This non-randomness in treatment assignment could create imbalanced baseline covari-
ates, i.e. confounding variables, and result in severe biased treatment effect estimate
if the confounding factors are not appropriately adjusted. Several methods have been
proposed to address the confounding problems in observational studies, such as match-
ing (e.g. Miettinen 1968), stratification (e.g. Cochran 1968), the instrumental variable
approach (e.g. Angrist et al. 1996) and various versions of propensity score methods
(e.g. Rosenbaum and Rubin 1983). Among them, the propensity score (PS) is one of
the most commonly used in practice.
Apart from its distinctive observational feature, another key feature of medical
record data is that treatment assignments are clustered. For example, the medical
record data are highly clustered by physicians, clinics, hospitals, and insurance agencies.
Real world medical data come from various sources that include insurance claim data,
hospital, and clinic prescription records, etc. Generally, a treatment that a patient
eventually receives depends on many factors which include but are not limited to: (1)
physician’s factors which include physician’s professional trainings, practice styles etc;
(2) patient’s factors which include patient’s age, gender, social economic status etc;
(3) system’s factors which include insurance policies, hospital policies , etc. All these
factors can create potential biases toward certain type of treatments. The clustering
feature of medical record data may reflect sample heterogeneity due to these factors
that can influence both the treatment allocation process as well as the disease outcomes.
Practical medical record data is not only clustered but also multilevel or hierar-
chically clustered. For example, patients are clustered within physicians who are also
further clustered within hospitals or clinics. As shown in the previous chapter, for med-
ical record data, both the observational and clustering features should be taken into
consideration for unbiased treatment effect estimates. In Chapter 3, we have developed
a robust propensity score model, i.e. SNP-PS, for single layer clustered data. Though
the proposed method is computationally more efficient than the existing Monte Carlo
sampling based semi-nonparametric approaches (e.g. Chen et al. 2002), it is not scaled
to handle large clustered medical record data. Typical medical record data contains
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medical records for a large number of patients, ranging from personal information like
age, demographics, social status to medical information such as blood pressure, family
disease history, medical history, medication and allergies, to immunization status for
each patient. Digitization of these records promotes the integration of hundreds of
thousands or even millions of patients into a large database from different resources
(e.g. Tinetti and Studenski 2011; Tannen et al. 2008; Weiner et al. 2008) such as
insurance claim data, hospital records, prescription records, and observational studies,
etc. It would be very computationally challenging to apply the method developed in
Chapter 3 to large clustered data directly. The computational challenge arises from
the facts that 1) we model the cluster effect in the logistic PS model where the MLEs
have no analytic closed form; and 2) the random effect in the logistic PS model is
non-parametrically modeled, making maximization on the likelihood even more com-
plicated. Developing computationally efficient statistical methods to properly handle
the heterogeneity structure of medical record data is more important than ever for
making valid statistical inferences.
To ease the computational workload, in this chapter, we propose to not model the
heterogeneity structure in the first stage logistic PS model and instead try to resolve the
heterogeneity problem in the second stage PS regression model. Specifically, we propose
two PS regression approaches, one based on the multiple regression model and the other
on the mixed effects model. The first one is a flexible multilevel propensity score (FM-
PS) regression approach based on mixed effects models. In traditional mixed effects
models, there is a critical independence assumption between fixed effects covariates
and random effects. However, this assumption is unrealistic and rarely holds for real
medical record data. For example, when patients make decisions where and which
clinic to visit, the physicians’ specialties, and insurance coverages play important roles.
These factors don’t act independently but jointly. They affect the treatment allocation
77
process and disease outcomes as well. Furthermore, the independence assumption is not
easy to check since the cluster effects are unobserved. If the assumption does not hold,
the estimates for the fixed effects parameters could be biased (Verbeke and Lesaffre
1996) and the degree of biasness depends on the degree of the correlation between the
fixed effect covariates and the cluster effects. We proposed FM-PS models to relax
the independence assumption between the treatment assignment and the heterogeneity
cluster effects for large clustered datasets. Under this modeling scheme, the cluster
effect is not necessarily independent of the fixed effects covariates or the cluster effects
from other clustering levels.
The remaining of this chapter is organized as follows. In Section 2, we describe the
details of FM-PS model. The theoretical properties of the treatment effect estimator
based on FM-PS are presented in this section also. A cluster bootstrapping procedure
is described in Section 3 for variance estimation of treatment effect estimate. We
provide a statistics to test the hypothesis of independence of the cluster effect terms
(with respect to other fixed effects terms) in Section 4 to select the optimal model for
treatment effect estimate. Extensive simulation studies and results are presented in
Section 5. The robustness property of FM-PS for dealing with model mis-specifications
and the capability/limitation to handle unobserved confounding covariates are also
investigated and presented in Section 5. The practical use of FM-PS is demonstrated
via a real multi-center observational dataset in Section 6. This chapter ends with
discussions and future research for FM-PS in Section 7.
4.2 Proposed Methods
4.2.1 Data Types
Before presenting the details of our proposed models, we first introduce three types
of clustered data (i.e. single level, multilevel, and hierarchical) that we consider in this
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chapter.
Single level clustered data (Type 1): for the jth sample nested in the cluster unit
i(j = 1, · · · , ni; i = 1, · · · , n), we define its outcome as yij, treatment assignment trtij,
and all other observed covariates as xij.
Multilevel clustered data (Type 2): for the kth sample in the ith level of clus-
ter 1 (e.g. physicians) and the jth level of cluster 2 (e.g. insurance policies) (k =
1, · · · , nij; i = 1, · · · , ni; j = 1, · · · , nj), we denote outcome as yijk, treatment assign-
ment trtijk and observed covariates xijk. Here the two clusters, i.e. 1 and 2, are not
nested one in another and potentially overlap. For example, the same physician may
see patients with all sorts of health insurances, and the same policy holders could visit
different physicians.
Hierarchical clustered data (Type 3): for the kth sample in the ith level of clus-
ter 1 (such as clinics/hospitals) and the jth level of cluster 2 (such as physicians)
(k = 1, · · · , nij; j = 1, · · · , ni; i = 1, · · · , n), we again have outcome yijk, treatment
assignment trtijk and observed covariates xijk. In contrast to Type 2 data, here units
of cluster 2 (e.g. physicians) are completely nested in units of cluster 1 (e.g. clinics).
Even though we only consider clustered data with single level or two levels for ease
of presentations, the proposed methods below can be straightforwardly extended to
higher level clustered data.
PS Model: For all types of data, we first fit the following logistic regression model
with only all the observed covariates included without any cluster effect terms
logit(Pr(trt = 1 | x)) = β0 + xβx, (4.1)
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from which we get the estimated PS score given by the following:
P̂S =
exp(βˆ0 + xβˆx)
1 + exp(βˆ0 + xβˆx)
where βˆ0 and βˆx are the MLE from model (4.1). That is we don’t deal with the cluster
effects in (4.1) and instead we take care of the clustering heterogeneity of treatment
assignment in the downstream PS regression analysis. Several random and fixed effects
PS regression models can be used for the above three types of clustered data to obtain
the treatment effect estimate as we describe in the following.
Standard Mixed Effects PS (SM-PS) Models: once PS are estimated from (4.1),
it is natural to fit the following mixed effects PS regression models:
Type 1 : yij = α0 + αtrttrtij + αPSP̂Sij + ηi + ij (4.2)
Type 2 : yijk = α0 + αtrttrtijk + αPSP̂Sijk + ηi + ξj + ijk (4.3)
Type 3 : yijk = α0 + αtrttrtijk + αPSP̂Sijk + ηij + ijk (4.4)
and obtain the corresponding treatment effect estimate, αˆtrt. However, the above mod-
els have a strong independence assumption imposed on the random effects. That is, all
cluster effect terms, i.e. ηi(j) and ξj, are independent of the fixed effects covariates, i.e.
trtij(k) and P̂Sij(k). Specifically, the SM-PS models assume the following:

Type 1: ηi | (trtij, P̂ Sij) ∼ N(0, σ2η)
Type 2: ηi | (trtijk, P̂ Sijk) ∼ N(0, σ2η) and ξj | (trtijk, P̂ Sijk) ∼ N(0, σ2ξ )
Type 3: ηij | (trtijk, P̂ Sijk) ∼ N(0, σ2η)
However, the above independence assumptions between the random cluster effects
and other fixed effects covariates including the treatment assignment seldom hold for
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many real world medical record data due to various confounding factors and complexity
of cluster heterogeneity structures in the treatment assignment process. If the inde-
pendence assumptions are violated, treatment effect estimate could be severely biased.
To relax the stringent independence assumptions made in the SM-PS models (4.2) ∼
(4.4), we propose a set of novel models as given in the following subsection. Specifi-
cally, we propose the following set of mixed effects propensity score regression models
for the above three types of data under the above corresponding assumptions. However,
it should be noted that the proposed method is not necessary restricted to the three
types of clustering. It is straightforward to extend the method to other higher level
clustering scenarios.
4.2.2 Flexible Mixed Effects PS (FM-PS) Models
For each of the three types of clustered data, we impose a dependence condition
between the random effects and fixed effects covariates:
Type 1: ηi | (trtij, P̂ Sij) ∼ N(αtrttrti + αPSPSi, σ2η)
Type 2:

ηi | (trtijk, P̂ Sijk) ∼ N(α(trt,1)trti + α(PS,1)PSi, σ2η)
ξj | (trtijk, P̂ Sijk) ∼ N(α(trt,2)trtj + α(PS,2)PSj, σ2ξ )
Type 3: ηij | (trtijk, P̂ Sijk) ∼ N(α(trt,2)trtij + α(PS,2)PSij, σ2η)
where the trts and PSs are the proportion of subjects receiving one given treatment
and the average propensity scores within each cluster/sub-cluster unit indicated by the
subscript, respectively. These conditions relieve the unrealistic independence assump-
tions and lead us to the following three flexible mixed effects PS (FM-PS) models, one
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for each data type.
Type 1 : yij = α0 + αtrttrtij + αPSP̂Sij + αtrttrti + αPSPSi + ηi + ij (4.5)
Type 2 : yijk = α0 + αtrttrtijk + αPSP̂Sijk + α(trt,1)trti + α(PS,1)PSi + α(trt,2)trtj
+α(PS,2)PSj + ηi + ξj + ijk (4.6)
Type 3 : yijk = α0 + αtrttrtijk + αPSP̂Sijk + αtrttrtij + αPSPSij + ηij + ijk (4.7)
where ηi(j) ∼ N(0, σ2η), ξj ∼ N(0, σ2ξ ), and  ∼ N(0, σ2), respectively. We refer the
new procedures as FM-PS which stands for Flexible Mixed effects Propensity Score
approaches. The new cluster effect terms η and ξ now follow the regular assumptions
in the standard mixed effects models (i.e. normality and independence, e.g. Laird and
Ware 1982; Schall 1991; Zeger and Karim 1991; Breslow and Clayton 1993).
The proposed approach is computationally efficient as will be shown by our simula-
tions. It can handle large medical record datasets with almost no constrains if memory
is of no concern. Modeling the single layer clustered or multilevel clustered data via
mixed effects model is not new (Diggle et al. 2002; Fitzmaurice et al. 2004). In prac-
tice, it is also common to use fixed effect models alternatively to analyze such kinds
of data with cluster effects modeled with dummy variables (Suits 1957). Alternatively,
we propose the following fixed effect models using dummy variables for the three types
of clustered data.
Fixed Effect PS (FE-PS) Models:
Type 1: yij = α0 + αtrttrtij + αPSP̂Sij + DViαDV + ij (4.8)
Type 2: yijk = α0 + αtrttrtijk + αPSP̂Sijk + DViαDV1 + DVjαDV2 + ijk (4.9)
Type 3: yijk = α0 + αtrttrtijk + αPSP̂Sijk + DVijαDV + ijk (4.10)
where the DVis and DVj are dummy variables created to represent units in cluster
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1 and cluster 2, respectively. In (4.10), for hierarchical clustered data, the dummy
variables DVij are created for units in cluster 2, which are nested in cluster 1.
The relationship between fixed effect models with dummy variables and mixed ef-
fects models have been well studied and the equivalence between the fixed effect esti-
mates from the two model strategies have been established by Mundlak (1978). The
following theorem summarizes the equivalence between the treatment effect estimates
from the FE-PS and FM-PS models. The proof can be found in Mundlak (1978).
Theorem 4.2.1. (Equivalence) The treatment effect estimate, denoted as αˆtrt, for
parameter αtrt in FM-PS models (4.5) and (4.7) are identical to the OLS estimate of
αtrt in models (4.8) and (4.10), respectively.
Though the above theorem has established the equivalence of the two PS procedures,
in practice, fitting the FE-PS models with ordinary linear regression using standard
software packages, e.g. R or SAS, might be computationally prohibited for large medical
data. However, FM-PS models have no such issues. Furthermore, the mixed effects
models are more flexible in extending the conclusions to patients from, for example
clinics and physicians not in the data analyzed. In contrast, conclusions based on fixed
effect models are restricted to the clinics and physicians included in the original data
analysis.
4.3 Variance Estimate of αˆtrt
As noted in the previous chapters, PS is an estimated quantity instead of an observed
covariate. Ignoring this fact will result in biased variance estimation for αˆtrt. In chapters
2 and 3, we proposed a two-stage variance estimator for PS regression models. The
validity of the two-stage variance estimator is based on the consistency of parameters
estimated from the first stage PS models. In the proposed FM-PS models, the first
stage PS models ignore the cluster effects and thus the parameter estimates may not
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be consistent and the two-stage variance estimators may not be applicable for the FM-
PS models. In this section, we propose a cluster bootstrapping procedure to estimate
the variance of αˆtrt for the proposed FM-PS models as we describe in the following.
The bootstrap technique by Efron (1979) has been often used in practice for infer-
encing on a population distribution based on the sample data (sample → population)
by resampling the sample data and performing inference on the resampled data (resam-
ple → sample). However, for the clustered data, the standard bootstrap resampling or
residual resampling procedure will not work (e.g. Liu and Chen 1998; Whitley 1994),
since it is not able to replicate the correlation structure in the data. Alternatively,
cluster bootstrapping (e.g. Davison and Hinkley 1997; McCullagh 2000; Andersson
and Karlsson 2001; Ukoumunne et al. 2003; Carpenter et al. 2003; Butar and Lahiri
2003; Monaco et al. 2005; Field and Welsh 2007) procedures have been proposed which
we adopt here for our purpose.
The idea of cluster bootstrapping is to treat each cluster unit as an independent
sample and randomly draw the n cluster units with replacement. All subjects within a
selected cluster unit will be included as bootstrapped samples and used for the boot-
strapping analysis. The cluster bootstrapping replicates the correlation structure by
resampling based on the “basic” cluster units. For single level clustered data, the “ba-
sic” sampling units are the original cluster units. Similarly, for hierarchical clustered
data, the sampling units are the cluster units in cluster 2, i.e. the lowest (finest) level
of clustering units (e.g. physicians in the clinics versus physicians hierarchical cluster-
ing relationship). For multilevel clustered data, we construct new cluster units as the
“basic” bootstrapping units. Specifically, each new cluster unit, ij, is the joint sub-unit
of ith level in cluster 1 and jth level in cluster 2. Cluster bootstrapping for multilevel
FM-PS model (4.6) is based on these reconstructed new cluster units. Simulations will
be used to investigate the performance of the proposed cluster bootstrapping approach.
84
4.4 Testing of Cluster Effects
If the cluster effect is independent of the fixed effect covariates, the SM-PS models
are expected to be more efficient than the FM-PS models. We propose the following
test statistic for comparing the SM-PS and FM-PS models. For the ease of illustration,
we use ζ to represent all the cluster effects (e.g. ζ = ({ηi}, {ξj}) in the outcome for the
multilevel cluster data) in each of the three FM-PS models. We refer the log-likelihood
from each of the FM-PS models as lFM−PS. Similarly, we refer the log-likelihood from
each of the SM-PS models as lSM−PS. Then, testing for independence is equivalent to
test
H0 : ζ ⊥ trt Ha : ζ 6⊥ trt (4.11)
To test the hypothesis (4.11), we introduce the following likelihood ratio test statistic:
LRTindep = −2 log Likelihood of SM-PS model
Likelihood of FM-PS model
= 2(lFM−PS − lSM−PS) (4.12)
∼H0 χ2(df)
where df , the degree of freedoms of the χ2 distribution, equals the difference between
the numbers of fixed covariates in the FM-PS and SM-PS models. More specifically,
df = 2, 4, and 2, respectively for the single level, multilevel, and hierarchical cluster
data. Statistics LRTindep provides a tool for us to select between the SM-PS and FM-PS
models.
In summary, the following are the procedures proposed to estimate treatment effects
for the clustered observational data:
Step 1: Fit the data with both SM-PS and FM-PS models.
Step 2: Use the test statistics LRTindep to select between SM-PS and FM-PS models.
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Step 3: Based on the selected model, estimate αtrt.
Step 4: Conduct the cluster bootstrapping procedure to obtain a valid variance estimate
of αˆtrt.
4.5 Monte Carlo Simulations
To evaluate the finite sample performance of the proposed FM-PS models and the
cluster bootstrapping procedure, we conduct intensive simulation studies under various
settings with varying sample size and heterogeneity correlation structures. We start
the simulation studies with the following settings for the three types of clustered data:
Treatment allocation model: In our first set of simulations, the treatment assign-
ments are generated for single, multilevel, and hierarchical clustered data through the
following mechanisms
Type 1: trtij =
 1 if 0.2 + x(1,ij)βx + wi + ij > 00 if 0.2 + x(1,ij)βx + wi + ij ≤ 0
Type 2: trtijk =
 1 if 0.2 + x(1,ijk)βx + wi + ijk > 00 if 0.2 + x(1,ijk)βx + wi + ijk ≤ 0
Type 3: trtijk =
 1 if 0.2 + x(1,ijk)βx + wij + ijk > 00 if 0.2 + x(1,ijk)βx + wij + ijk ≤ 0
respectively, where confounding covariate vectors x(1,ij(k)) = (x(1,ij(k),1), · · · ,x(1,ij(k),8))′
consists 8 covariates. Pairs of confounding covariates are generated from binary, normal,
exponential, and uniform distributions as Bern(0.5), N(0, 1), Exp(1), and Unif(−1, 1),
respectively. Parameter βx,js in βx = (βx,1, · · · , βx,8)′ are randomly generated from
Unif(−1, 1) first and then fixed for all the subsequent simulations. The random mea-
surement error  ∼ N(0, 1). The distribution of cluster effects wi(j) will be described
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later.
Data generating model: The responses are generated based on the following mech-
anisms for the three types of clustered data:
Type 1: yij = 0.3 + αtrttrtij + x(1,ij)αx + ηi + εij (4.13)
Type 2: yijk = 0.3 + αtrttrtijk + x(1,ijk)αx + ηi + ξj + εijk (4.14)
Type 3: yijk = 0.3 + αtrttrtijk + x(1,ijk)αx + ηij + εijk (4.15)
where the random measurement error εij(k) ∼ N(0, 1) which is independent of trtij(k),
x(1,ij(k) and cluster effects ηi(j) and ξj. The true treatment effect αtrt is fixed at 0.5.
The effect of each confounding covariate, αx,j (j = 1, · · · , 8), is also randomly generated
from Unif(−1, 1) and fixed for all subsequent simulations.
The cluster effects in the treatment assignment models and the response generating
models are sampled from non-normal distributions, and are correlated or independent
of each other. Specifically, we let the cluster effect wi in the treatment assignments and
the cluster effect ηi in outcome responses (4.13) and (4.14) be correlated as follows:
ηi ∼
 wi if wi ≥ 0−Exp(1) if wi < 0
where wi ∼ 12Exp(2) + 12N(−0.5, 1).
The cluster effects wijs and ηijs are simulated similarly as above where the subscript
i is replaced by the subscript ij. For the case where wi(j)s are independent of ηi(j)s, ηi(j)
are simulated from 1
2
Exp(1) + 1
2
N(−1, 1) while wi(j) is generated the same as above.
For multilevel clustering, we further simulate the cluster effects ξj from
1
2
N(2, 1) +
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1
2
N(−2, 1).
To mimic the real world observational data, in addition to the true confounding
covariates x(1,ij(k)), we also simulate an additional set of 8 nuisance variables, x(2,ij(k)).
Again, pairs of the 8 nuisance variables are generated from Bern(0.5), N(0, 1), Exp(1),
and Unif(−1, 1), respectively. These nuisance variables have no effects on either the
response variable y or the treatment assignment trt. However, we include them in our
analysis. That is we include all of the 16 covariates xij(k) = (x
′
(1,ij(k)),x
′
(2,ij(k)))
′
in our
analysis to obtain the estimation for PS.
To evaluate the performance of the proposed FM-PS models, we compare them
with several other competing models, which include 1) unadjusted model where the
treatment effect estimate equals the response difference between the two treatment
groups without any confounding covariate adjustment; 2) non-random PS (NR-PS)
model where the treatment effect estimate is obtained via the simple PS regression
in which propensity scores are estimated by the PS model (4.1) without considering
unobserved heterogeneity; 3) the SM-PS models; and 4) the FE-PS models.
For the single level clustering data, we simulate samples with size n of 1000 or 5000.
The cluster cell sizes vary from 5, 10, or 15 with total cluster units of 100 and 500
respectively for the two sample sizes. Simulation results for these two sample sizes are
summarized in Table (4.1) and (4.2), respectively for correlated and independent clus-
ter effects between treatment assignments and outcomes. For each simulation setup,
the results are based on 500 simulations and the cluster bootstrapping is conducted
with 500 resampling. Column “Independence” indicates if the cluster effect in treat-
ment assignment and the cluster effect in outcome are independent or not. Column
“Average(αˆtrt)” represents the average treatment effect estimate, column “Monte Carlo
SD(αˆtrt)” shows the Monte Carlo standard deviation of the treatment effect estimate,
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column “Average ŜED(αˆtrt)” presents the average standard error for the treatment
effect estimate output directly from the corresponding model fitting, and column “Av-
erage ŜEB(αˆtrt)” displays the average standard error for the treatment effect estimate
via the cluster bootstrapping procedure.
Tables (4.1) and (4.2) show that when cluster effect wis in treatment assignment
and that in response ηis are independent of each other, the treatment effect estimated
by all methods except the unadjusted model are close to the true treatment effect size,
indicating the effectiveness of all the PS based methods in adjusting the confounding
factors. However, a closer examining the second part of both tables reveals that when
wis and ηis are correlated, only the FE-PS model and the proposed FM-PS model
can provide unbiased treatment effect estimates. Furthermore, the estimates from the
two models are identical which is consistent with the conclusion of Theorem 4.2.1. In
contrast, the treatment effect estimates from the NR-PS model and the SM-PS model
are biased.
Comparing the columns Monte Carlo SD(αˆtrt) and ŜED(αˆtrt), we conclude that for
the proposed FM-PS model, the default variance estimates are biased. For example,
when sample size n = 1000, the Monte Carlo standard deviation from the FM-PS model
is 0.117 while the default standard error is 0.159 where the later number is more than
30% larger than the former one. This observation holds for n = 5000 (i.e. 0.054 vs
0.070). In contrast, numbers in column Monte Carlo SD(αˆtrt) and column ŜEB(αˆtrt)
are close to each other for all models and sample sizes, demonstrating the superior
performance of the cluster bootstrapping procedure.
For multilevel clustering data, we fix cluster cell size of cluster 1 as 5 with total
1000 cluster units while we let the cluster cell size for cluster 2 varies from 100 to 900
among total 10 cluster units. For hierarchical clustering data, again we set cluster cell
size for cluster 1 to 5 with total 1000 cluster units which are nested within 500 units in
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cluster 2 with cell size 10. Simulation results for multilevel and hierarchical clustering
scenarios with sample size n = 5000 are presented in Tables (4.3) and (4.4) respectively.
Table (4.3) and (4.4) demonstrate that when wi (or wij) and ηi (or ηij) are indepen-
dent of each other for multilevel and hierarchical clustered data, we again can obtain
unbiased treatment effect estimates from all the four PS procedures, though the un-
adjusted model fails. For data with correlated cluster effects, only estimates from the
FE-PS and FM-PS models are unbiased. Similarly, the default variance estimates are
biased which can be drastically improved by the cluster bootstrapping procedure.
All four tables consistently demonstrate that when the cluster effects in treatment
assignments are independent of the cluster effects in the responses, the treatment effect
estimate from SM-PS model is more efficient than the proposed FM-PS (or FE-PS)
models. Thus, the SM-PS model is preferred for data where the cluster effects are
independent of the fixed effect covariates. The proposed likelihood ratio test statistic,
i.e. LRTindep, serves the purpose to select the optimum model by testing the indepen-
dence assumption. To investigate the performance of LRTindep, we generate several
Q-Q plots of the empirical LRTindep against the theoretical χ
2 distribution for the data
with independent cluster effects for the three types of clustered data with sample size
n = 5000 in Figures (4.1) ∼ (4.3).
All Q-Q plots clearly indicate that the empirical test statistics follow the asymptotic
χ2 distribution well. For all data simulated with correlated cluster effects, we also
plot the observed LRTindep across the 500 simulations. In addition, we add the 500
LRTindep observed values for the data with independent cluster effects. Clearly, the
empirical LRTindep from the data under the null (i.e. independent situations) and
under the alternative (i.e. correlated situations) are well separated, indicating that for
the simulated correlated data, the proposed LRTindep has very good power to detect
the correlation.
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In summary, the proposed FM-PS models (or equivalent FE-PS models) provide
unbiased treatment effect estimates no matter if the cluster effects in treatment as-
signments are independent of the cluster effects in the responses or not. Traditional
SM-PS models provide more efficient and unbiased treatment effect estimates than the
proposed models when the cluster effects in treatment allocations are independent of
the cluster effects in the responses. However, when the cluster effects are correlated,
the treatment effect estimates from SM-PS models are biased. The empirical cluster
bootstrapping procedure provides good variance estimation to αˆtrt.
The above simulations have shown that the proposed FM-PS models are robust to
the departure of cluster effects η and ξ from normality distributions, because in all our
simulations, the cluster effects are non-normally distributed. Next, we further investi-
gate the robustness property of the FM-PS models with other model misspecification
scenarios under the single level clustering setting. The conclusions hold for other two
types of data and are omitted.
Link function misspecification: we first design the following simulation setting
where the treatment allocation does not follow linear logit link functions. Specifically,
we simulate trt from
logit(Pr(trtij = 1 | xij)) ∼

(τij+1)
1.5−1
1.5
if τij ≥ 0
− (τij+1)1.2−1
1.2
if τij < 0
with τij = −0.5x(1,ij) + 0.3x(2,ij) + wi, x(1,ij) ∼ Bern(0.5) and x(2,ij) ∼ N(0, 1).
The responses are generated from the following model:
yij = 0.3 + 0.5trtij + 0.3x(1,ij) + 0.2x(2,ij) + ηi + ij
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where ij ∼ N(0, 1). ηi = bκi where κi ∼ N(0.5, 1) and we set b to 0 or 0.3. The cluster
effect wi in treatment assignments is correlated with κi in responses as the following:
wi ∼
 N(0.55, 1) if κi ≥ 0N(−0.45, 1) if κi < 0.
Covariate functional form misspecification: To further demonstrate the robust-
ness of FM-PS model, we design the following simulation setting:
yij = 0.3 + 0.5trtij + 0.3x(1,ij) + 0.2x
2
(2,ij) + ηi + ij
where ij, x(1,ij), x(2,ij), and ηi are simulated the same way as the above link func-
tion misspecification scenario. Treatment is allocated via the following thresholding
mechanism:
trtij =
 1 if −0.5x(1,ij) + 0.3x
3
(2,ij) + wi + δij > 0
0 if −0.5x(1,ij) + 0.3x3(2,ij) + wi + δij ≤ 0
with δij ∼ N(0, 1) and wi is set the same as in the above link function misspecification
scenario. Note, in this simulation setting, covariate x2,ij affects both the response and
the treatment allocation nonlinearly.
In all four propensity score based models we compared (i.e. NR-PS, SM-PS, FE-PS
and FM-PS models), the propensity scores are estimated by the propensity score model
(4.1) where only the linear covariate terms are included. Simulation results with sample
size n = 10000 are summarized in Tables (4.5) and (4.6). Both tables show that the
proposed FM-PS models are robust to data that are generated from the non-linear logit
link function or the non-linear confounding covariate functional form. Furthermore, the
cluster bootstrapping procedure gives valid variance estimation for αˆtrt in these model
misspecification scenarios.
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The existence of unobserved confounding covariatesis likely to result in biased pa-
rameter estimates. Various methods have been proposed to deal with the unobserved
confounding covariate from different aspects (e.g. Rosenbaum and Rubin 1983b; Lin
et al. 1998; Sturmer et al. 2005). We investigate the performance of the proposed
FM-PS models in handling hidden confounding covariates that are at cluster level, or
at sample individual level under the single level clustering scenario.
Cluster level unobserved (hidden) confounding covariate: The treatment as-
signment trtij is generated via the following mechanism:
trtij =
 1 if 0.2− 0.7x(1,ij) − 0.4x(2,ij) + 0.7x(3,ij) + 0.4x(4,i) + wi + υij > 00 if 0.2− 0.7x(1,ij) − 0.4x(2,ij) + 0.7x(3,ij) + 0.4x(4,i) + wi + υij ≤ 0
where υij ∼ N(0, 1) is a random measurement error. The response yij is generated
from the following model:
yij = 0.3 + 0.5trtij − 0.6x(1,ij) − 0.3x(2,ij) + 0.6x(3,ij) + 0.3x(4,i) + ηi + ij
where ij ∼ N(0, 1), x(1,ij) ∼ Bern(0.5), x(2,ij) ∼ N(0, 1) and x(3,ij) ∼ Exp(1). Cluster
effect wi is correlated with ηi as follows:
wi ∼
 ηi if ηi ≥ 0−Exp(1) if ηi < 0
where ηi ∼ 12Exp(2) + 12N(−0.5, 1).
When wi and ηi are independent, we have wi ∼ 12Exp(1) + 12N(−1, 1) and ηi ∼
1
2
(−Exp(2)) + 1
2
Exp(1.5).
The confounding variable x(4,i) ∼ 12Unif(−1, 1) + 12N(0, 1) is assumed to be unob-
served and not included as a covariate in the PS models investigated.
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Subject level unobserved confounding covariate: The simulation settings under
this scenario for treatment assignment and response are nearly the same as above except
that the unobserved confounding covariate, x4,i now varies at the subject level, and we
indexed this variable as x(4,ij) which follows Unif(−0.5, 1).
Again, four nuisance covariates, from Bern(0.5), N(0, 1), Exp(1), and Unif(−1, 1)
are generated. When estimating propensity scores, only covariates, x(1,ij), · · · , x(3,ij),
and the nuisance covariates are included in Model (4.1). Simulation results for the
unobserved confounding covariate at the cluster level and subject level are given in
Table (4.7) and (4.8), respectively.
Table (4.7) demonstrates that FM-PS and FE-PS can provide unbiased treatment
effect estimates in the existence of cluster level unobserved confounding covariate. Un-
der this setting, no matter if the cluster effect in treatment assignment is independent
of or correlated with the cluster effect in response, the treatment effects estimated by
other PS based models, i.e. NR-PS and SM-PS, are severely biased. Checking this table
also reveals that the cluster bootstrapping procedure provides valid variance estimate
for αˆtrt. This observation indeed matches what we observed earlier. This makes sense
since the random cluster effects in the FM-PS and FE-PS automatically account for the
effects of the cluster level unobserved confounding covariates. In contrast, the treatment
effects estimated by NR-PS and SM-PS models are all biased in all situations. How-
ever, Table (4.8) indicates that the treatment effects estimated by all models including
FM-PS and FE-PS are biased in the existence of subject level unobserved confounding
covariates since the strongly ignorable treatment assignment assumption is violated and
no any PS approach is powerful enough to handle this confounding problem.
In summary, for unobserved confounding covariates, if they are highly correlated
with other observed covariates and/or cluster effects then the treatment effect estimated
by our proposed FM-PS model will be unbiased. But this conclusion may not hold for
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NR-PS and SM-PS models. However, if the unobserved confounding covariate(s) is
at the subject level and not highly correlated with any other observed covariates and
cluster effects, the strongly ignorable treatment assignment assumption can not hold
and none of the methods gives unbiased treatment effect estimates.
4.6 Real Data Analysis
To demonstrate the practical use of the proposed FM-PS regression model, we
applied it to a multi-center breast cancer study conducted by the German Breast Cancer
Study Group (Rauschecker et al. 1995) that we described in details in Section 3.6 of
Chapter 3. Based on the preliminary analysis there, the observed covariates include
age (i.e. Age), tumor size (i.e. TS), and their interactions. Therefore, we use the
following logistic regression model to estimate the propensity scores for the downstream
PS regression analysis with analysis results presented in Table 4.9:
logit{PSi(= Pr(trti = 1 | (Agei, TSi)))} = γ0 + γ1 ∗ Agei + γ2 ∗ TSi + γ3 ∗ Agei ∗ TSi
From Table 4.9, an evident observation is that the treatment effect estimate based
on the unadjusted model is larger than that based on other methods. After adjusting
the confounding factors based on different versions of PS methods, the treatment effect
estimates are reduced. Different estimation schemes give us quite different but positive
treatment effect estimates. The positive number indicates that the QoL for the breast
conservation group patients is on average better than that of mastectomy group pa-
tients. However, this conclusion is not statistically significant. This can be confirmed
by checking the corresponding 95% confidence interval (i.e. column 95% CI).
Overall, based on the data collected for this multi-center study, there exists no
statistically significant difference on the QoLs of breast cancer patients between the
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two treatment procedures after adjusting the patient age, tumor size, their interaction
and the cluster effect.
4.7 Discussions
In this chapter, we have developed a flexible mixed effects propensity score (FM-PS)
approach to model the hidden heterogeneity structure of medical record data. The FM-
PS models relax the unrealistic independence assumption made by traditional mixed
effects models between the random effects and the fixed effect covariates. Due to treat-
ment allocation dynamics in real world data, this assumption rarely holds, especially
for clustered medical record data. The heterogeneity across cluster units may influence
both treatment allocations as well as disease outcomes. The proposed FM-PS frame-
work relaxes the independence assumption by incorporating the proportion of patients
assigned to one of the two treatment groups and the average of propensity scores for
each cluster unit as additional covariates into traditional mixed effects models. Includ-
ing these additional covariates effectively captures complicated correlation structures
between the cluster effects and fixed effect covariates. We further show that there ex-
ists equivalence between the FM-PS and the FE-PS models for estimating treatment
effects. However, our investigations (not shown) have indicated that the FM-PS models
are more computationally efficient for handling large medical data. We have repeated
another set of simulations with the simulation setting of Table (4.1) where sample size
n is increased to 500,000 with the number of cluster units 100,000. This number is
not unrealistic for electronic medical data. Interestingly, the FM-PS models run well
with R function of lmer in package lme4 for this simulation but the FE-PS models
fail in R with the lm function due to a large number of dummy variables that need
to be created. The FM-PS models require much less computational workload for data
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with a large number of cluster units and thus is more practically useful for large data
like electronic medical record data where there exist hundreds and thousands of cluster
units (i.e. physicians and/or clinics).
Our simulation results demonstrated that when the independence assumption for
the cluster effects does not hold, the treatment effect estimated from SM-PS model and
NR-PS model can be severely biased. However, both the proposed FM-PS and the FE-
PS approach provide unbiased treatment effect estimates. Additionally, we demonstrate
the robustness of FM-PS approach under various model misspecification. The proposed
FM-PS approach can be extended to higher level clustered data straightforwardly but
further research is needed to check the performance of extended methods in this regard.
Even though the proposed FM-PS approach can provide unbiased treatment effect
estimate no matter if the independence assumption for the cluster effect term holds or
not, the estimate is not as efficient as that from the SM-PS model when the indepen-
dence assumption does hold. We propose a likelihood ratio test statistic to test the
independence, which provides us a guidance on selecting an appropriate PS approach
for each data.
Under the propensity score adjustment framework, Rosenbaum and Rubin (1983)
have shown that the treatment effect estimate is unbiased if there is no unobserved
confounding (i.e. strongly ignorable treatment assignment assumption). In real world
observational data, due to the complexity in treatment allocation and factors influ-
encing the outcome, the strong ignorable treatment assignment assumption may not
hold. Our simulation studies further show that the proposed FM-PS models can handle
unobserved confounding covariates reasonably well under certain simple circumstances.
The performance of FM-PS with more complicated unobserved confounding factors is
very critical and deserve further investigations.
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Figure 4.1: Single Level Clustering with Sample Size=5000
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Figure 4.2: Multilevel Clustering with Sample Size=5000
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Figure 4.3: Hierarchical Clustering with Sample Size=5000
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Table 4.1: Single Level Clustering with Sample Size=1000
Monte Carlo Average Average
Model Independence Average(αˆtrt) SD(αˆtrt) ŜED(αˆtrt) ŜEB(αˆtrt)
Unadjusted
Yes
0.754 0.111 0.112 0.111
NR-PS 0.498 0.083 0.137 0.085
SM-PS 0.500 0.087 0.144 0.093
FE-PS 0.503 0.117 0.159 0.120
FM-PS 0.503 0.117 0.159 0.120
Unadjusted
No
0.754 0.111 0.112 0.111
NR-PS 0.747 0.085 0.137 0.087
SM-PS 0.636 0.094 0.144 0.098
FE-PS 0.503 0.117 0.159 0.120
FM-PS 0.503 0.117 0.159 0.120
Note: Results are based on 500 simulations & true αtrt = 0.5
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Table 4.2: Single Level Clustering with Sample Size=5000
Monte Carlo Average Average
Model Independence Average(αˆtrt) SD(αˆtrt) ŜED(αˆtrt) ŜEB(αˆtrt)
Unadjusted
Yes
0.759 0.047 0.050 0.050
NR-PS 0.501 0.037 0.060 0.038
SM-PS 0.502 0.040 0.064 0.042
FE-PS 0.500 0.054 0.070 0.054
FM-PS 0.500 0.054 0.070 0.054
Unadjusted
No
0.759 0.047 0.050 0.050
NR-PS 0.754 0.038 0.060 0.039
SM-PS 0.636 0.042 0.064 0.044
FE-PS 0.500 0.054 0.070 0.054
FM-PS 0.500 0.054 0.070 0.054
Note: Results are based on 500 simulations & true αtrt = 0.5
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Table 4.3: Multilevel Clustering with Sample Size=5000
Monte Carlo Average Average
Model Independence Average(αˆtrt) SD(αˆtrt) ŜED(αˆtrt) ŜEB(αˆtrt)
Unadjusted
Yes
1.263 0.067 0.052 0.049
NR-PS 0.509 0.074 0.081 0.064
SM-PS 0.503 0.036 0.053 0.038
FE-PS 0.505 0.061 0.066 0.058
FM-PS 0.505 0.061 0.066 0.058
Unadjusted
No
1.265 0.082 0.075 0.068
NR-PS 0.937 0.079 0.082 0.064
SM-PS 0.801 0.059 0.056 0.058
FE-PS 0.505 0.061 0.066 0.058
FM-PS 0.505 0.061 0.066 0.058
Note: Results are based on 500 simulations & true αtrt = 0.5
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Table 4.4: Hierarchical Clustering with Sample Size=5000
Monte Carlo Average Average
Model Independence Average(αˆtrt) SD(αˆtrt) ŜED(αˆtrt) ŜEB(αˆtrt)
Unadjusted
Yes
1.173 0.060 0.056 0.059
NR-PS 0.503 0.057 0.064 0.058
SM-PS 0.502 0.042 0.062 0.044
FE-PS 0.502 0.067 0.074 0.067
FM-PS 0.502 0.067 0.074 0.067
Unadjusted
No
1.259 0.053 0.064 0.052
NR-PS 0.803 0.046 0.062 0.046
SM-PS 0.636 0.042 0.064 0.044
FE-PS 0.502 0.067 0.074 0.067
FM-PS 0.502 0.067 0.074 0.067
Note: Results are based on 500 simulations & true αtrt = 0.5
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Table 4.5: Link Function Misspecification with Sample Size=10000
Monte Carlo Average Average
Model Independence Average(αˆtrt) SD(αˆtrt) ŜED(αˆtrt) ŜEB(αˆtrt)
Unadjusted
Yes (i.e. b = 0)
0.519 0.020 0.021 0.021
NR-PS 0.500 0.020 0.021 0.020
SM-PS 0.500 0.021 0.022 0.021
FE-PS 0.499 0.027 0.026 0.027
FM-PS 0.499 0.027 0.026 0.027
Unadjusted
No (i.e. b 6= 0)
0.612 0.022 0.021 0.022
NR-PS 0.596 0.022 0.022 0.022
SM-PS 0.549 0.022 0.023 0.022
FE-PS 0.499 0.027 0.026 0.027
FM-PS 0.499 0.027 0.026 0.027
Note: Results are based on 500 simulations & true αtrt = 0.5
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Table 4.6: Covariate Functional Form Misspecification with Sample Size=10000
Monte Carlo Average Average
Model Independence Average(αˆtrt) SD(αˆtrt) ŜED(αˆtrt) ŜEB(αˆtrt)
Unadjusted
Yes (i.e. b = 0)
1.173 0.060 0.056 0.059
NR-PS 0.503 0.057 0.064 0.058
SM-PS 0.502 0.042 0.062 0.044
FE-PS 0.502 0.067 0.074 0.067
FM-PS 0.502 0.067 0.074 0.067
Unadjusted
No (i.e. b 6= 0)
1.259 0.053 0.064 0.052
NR-PS 0.803 0.046 0.062 0.046
SM-PS 0.636 0.042 0.064 0.044
FE-PS 0.502 0.067 0.074 0.067
FM-PS 0.502 0.067 0.074 0.067
Note: Results are based on 500 simulations & true αtrt = 0.5
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Table 4.7: Cluster Level Unobserved Confounding with Sample Size=5000
Monte Carlo Average Average
Model Independence Average(αˆtrt) SD(αˆtrt) ŜED(αˆtrt) ŜEB(αˆtrt)
Unadjusted
Yes
1.131 0.042 0.036 0.039
NR-PS 0.593 0.039 0.034 0.038
SM-PS 0.552 0.037 0.036 0.036
FE-PS 0.501 0.042 0.040 0.040
FM-PS 0.501 0.042 0.040 0.040
Unadjusted
No
1.360 0.040 0.036 0.039
NR-PS 0.862 0.041 0.034 0.040
SM-PS 0.687 0.039 0.036 0.038
FE-PS 0.501 0.042 0.040 0.040
FM-PS 0.501 0.042 0.040 0.040
Note: Results are based on 500 simulations & true αtrt = 0.5
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Table 4.8: Subject Level Unobserved Confounding with Sample Size=5000
Monte Carlo Average Average
Model Independence Average(αˆtrt) SD(αˆtrt) ŜED(αˆtrt) ŜEB(αˆtrt)
Unadjusted
Yes
1.074 0.039 0.037 0.038
NR-PS 0.522 0.036 0.034 0.036
SM-PS 0.526 0.034 0.035 0.035
FE-PS 0.534 0.040 0.041 0.040
FM-PS 0.534 0.040 0.041 0.040
Unadjusted
No
1.311 0.037 0.036 0.037
NR-PS 0.800 0.037 0.034 0.037
SM-PS 0.701 0.036 0.036 0.037
FE-PS 0.534 0.040 0.041 0.040
FM-PS 0.534 0.040 0.041 0.040
Note: Results are based on 500 simulations & true αtrt = 0.5
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Table 4.9: Multilevel Analysis for German Breast Cancer Study Data
Average Average
Model αˆtrt ŜED(αˆtrt) ŜEB(αˆtrt) 95% CI
Unadjusted 1.533 1.279 1.527 (-1.460,4.526)
NR-PS 0.725 1.322 1.507 (-2.229,3.679)
SM-PS 1.076 1.374 1.326 (-1.523,3.675)
FE-PS 1.213 1.436 1.402 (-1.535,3.961)
FM-PS 1.213 1.436 1.402 (-1.535,3.961)
Note: Results based on 500 cluster bootstrap resampling
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Chapter 5
Future Research
In this dissertation, we have proposed a two-stage variance estimation scheme for
PS regression models and different PS methods for dealing with the heterogeneity in
treatment assignment process for clustered data. Even though we have conducted
research under various settings for the proposed methods, they are all based on the
continuous response data type. Potential extensions for the proposed methods and
other related research include the following:
5.1 Extending the Proposed Methods to Other Types of Data
In the future research, we plan to extend our PS models from continuous response
variables to other types of response variables commonly observed in CER studies, such
as the binary cure versus non-cure events, and time to event data (i.e. cure or death).
We plan to combine techniques such as multinomial or ordered logit, parametric and
non-parametric survival analysis with the proposed PS models where the treatment
assignment is heterogeneous. Longitudinal resources where patients are followed up
over years of medical interventions, which frequently exist in observational data, would
provide us with great opportunities to assess true treatment effects yet at the same time
pose more challenges in dealing with time-dependent confounding. Developing robust
PS models that adjust time-dependent confounding will be one of our future research
focus.
5.2 Developing New Methods with Missing Confounding Factors
Missing data is a commonly occurring complication in scientific investigations. In
CER studies, missing important confounding covariates could have a significant impact
on the validity of the estimation of the true treatment effect. Determining the appro-
priate analytic approach in the presence of incomplete observations is a major problem
for data analysts. The development of statistical methods to address missing data has
been an active area of research. For heterogeneous observational data, we plan to com-
bine nonparametric kernel regression methods for missing important variable with the
proposed PS models under various data missing mechanisms.
In addition, for CER studies with missing important confounding covariates, often
there exist some readily available auxiliary covariates information. Auxiliary informa-
tion can also be obtained from inaccurate measures of the confounding variables. For
example, it is found that the self reported height is often inflated in males. Other situa-
tions where auxiliary confounding information arises are where the exposure assessment
relies on the subjects responses to questionnaires, or the exposure of interest may be
too difficult or expensive to obtain. In such situations, a related variable may be used
as an auxiliary variable for the exposure of interest. There are some existing methods
in the statistical literatures on using auxiliary variables, however, there is few research
on using the auxiliary variable in sharpening the estimation of the treatment effects,
not to mention under the intractable heterogeneity found in the treatment assignment.
We plan to extend the proposed PS methods to data with auxiliary covariates.
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APPENDIX I: PROOF OF THEOREM 2.3.1
Proof. Denote θ?1 and θ
?
2 as the true parameter values of θ1 and θ2 under the models
(2.2) and (2.3). Following similar procedures of Murphy and Topel (1985), with the
notations defined in Section 2.3, the MLE of θ1 and θ2, i.e. θˆ1 and θˆ2 derived from
Stage 1 and 2 models satisfy the following score equations:
n∑
i=1
∂l1,i(θˆ1)
∂θ1
= 0
n∑
i=1
∂l2,i(θˆ1, θˆ2)
∂θ2
= 0
Under the standard regularity conditions, θˆ1 is consistent. Therefore, the maximiza-
tion of quantity 1
n
∑n
i=1 l2,i(θˆ1,θ2) is asymptotically equivalent to the maximization of
1
n
∑n
i=1 l2,i(θ
?
1,θ2). Thus, θˆ2 is consistent.
Taking Taylor expansions on
∂l1,i(
ˆθ1)
∂θ1
and
∂l2,i(
ˆθ1,
ˆθ2)
∂θ2
at θ? = (θ?1,θ
?
2), we obtain the
following approximations:
∂l1,i(θˆ1)
∂θ1
≈ ∂l1,i(θ
?
1)
∂θ1
+
∂2l1,i(θ
?
1)
∂θ1∂θ
T
1
(θˆ1 − θ?1)
∂l2,i(θˆ1, θˆ2)
∂θ2
≈ ∂l2,i(θ
?
1,θ
?
2)
∂θ2
+
∂2l2,i(θ
?
1,θ
?
2)
∂θ2∂θ
T
1
(θˆ1 − θ?1) +
∂2l2,i(θ
?
1,θ
?
2)
∂θ2∂θ
T
2
(θˆ2 − θ?2)
Plugging the above two terms into the score equations, we immediately obtain the
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following:
− 1√
n
n∑
i=1
∂l1,i(θ
?
1)
∂θ1
≈ 1
n
{
n∑
i=1
∂2l1,i(θ
?
1)
∂θ1∂θ
T
1
}√n(θˆ1 − θ?1) (5.1)
− 1√
n
n∑
i=1
∂l2,i(θ
?
1,θ
?
2)
∂θ2
≈ 1
n
{
n∑
i=1
∂2l2,i(θ
?
1,θ
?
2)
∂θ2∂θ
T
1
}√n(θˆ1 − θ?1)
+
1
n
{
n∑
i=1
∂2l2,i(θ
?
1,θ
?
2)
∂θ2∂θ
T
2
}√n(θˆ2 − θ?2) (5.2)
By the central limit theorem, we conclude that the joint distribution of statistics
− 1√
n
∑n
i=1
∂l1,i(θ
?
1)
∂θ1
and − 1√
n
∑n
i=1
∂l2,i(θ
?
1,θ
?
2)
∂θ2
is normal and given by the following:
 − 1√n∑ni=1 ∂l1,i(θ
?
1)
∂θ1
− 1√
n
∑n
i=1
∂l2,i(θ
?
1,θ
?
2)
∂θ2
→ N(0,V)
where V =
( V−11 (θ1) R(θ1,θ2)
R(θ1,θ2) V−12 (θ2)
)
.
By the law of large number theorem, the asymptotic equivalence of (5.1) can be
written as the following:
√
n(θˆ1 − θ?1) ≈ V1(θ1)
1√
n
n∑
i=1
∂l1,i(θ
?
1)
∂θ1
(5.3)
Plugging (5.3) into (5.2) and applying the law of large number theorem again, we
have:
√
n(θˆ2 − θ?2) ≈ V2(θ2)C(θ1,θ2)V1(θ1)
1√
n
n∑
i=1
∂l1,i(θ
?
1)
∂θ1
+ V2(θ2)
1√
n
n∑
i=1
∂l2,i(θ
?
1,θ
?
2)
∂θ2
By the joint distribution of − 1√
n
∑n
i=1
∂l1,i(θ
?
1)
∂θ1
& − 1√
n
∑n
i=1
∂l2,i(θ
?
1,θ
?
2)
∂θ2
, we obtain
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the asymptotic distribution of θˆ2:
√
n(θˆ2 − θ?2)→ N(0,Σ)
where Σ = V2+V2[CV1C
T−RV1CT−CV1RT ]V2 and conclusions follow immediately.
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APPENDIX II: PROOF OF THEOREM 3.4.1
Proof. Denote θ?1 and θ
?
2 as the true parameter values of θ1 and θ2 under the models
(3.3) and (3.6). Following similar procedures of Murphy and Topel (1985), with the
notations defined in Section 3.4, the MLE of θ1 and θ2, i.e. θˆ1 and θˆ2 derived from
models (3.3) and (3.6) satisfy the following score equations:
n∑
i=1
∂l1,i(θˆ1)
∂θ1
= 0
n∑
i=1
∂l2,i(θˆ1, θˆ2)
∂θ2
= 0
Under the standard regularity conditions, θˆ1 is consistent. Therefore, the maximiza-
tion of quantity 1
n
∑n
i=1 l2,i(θˆ1,θ2) is asymptotically equivalent to the maximization of
1
n
∑n
i=1 l2,i(θ
?
1,θ2). Thus, θˆ2 is consistent.
Taking Taylor expansions on
∂l1,i(
ˆθ1)
∂θ1
and
∂l2,i(
ˆθ1,
ˆθ2)
∂θ2
at θ? = (θ?1,θ
?
2), we obtain the
following approximations:
∂l1,i(θˆ1)
∂θ1
≈ ∂l1,i(θ
?
1)
∂θ1
+
∂2l1,i(θ
?
1)
∂θ1∂θ
T
1
(θˆ1 − θ?1)
∂l2,i(θˆ1, θˆ2)
∂θ2
≈ ∂l2,i(θ
?
1,θ
?
2)
∂θ2
+
∂2l2,i(θ
?
1,θ
?
2)
∂θ2∂θ
T
1
(θˆ1 − θ?1) +
∂2l2,i(θ
?
1,θ
?
2)
∂θ2∂θ
T
2
(θˆ2 − θ?2)
Plugging the above two terms into the score equations, we immediately obtain the
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following:
− 1√
n
n∑
i=1
∂l1,i(θ
?
1)
∂θ1
≈ 1
n
{
n∑
i=1
∂2l1,i(θ
?
1)
∂θ1∂θ
T
1
}√n(θˆ1 − θ?1) (5.4)
− 1√
n
n∑
i=1
∂l2,i(θ
?
1,θ
?
2)
∂θ2
≈ 1
n
{
n∑
i=1
∂2l2,i(θ
?
1,θ
?
2)
∂θ2∂θ
T
1
}√n(θˆ1 − θ?1)
+
1
n
{
n∑
i=1
∂2l2,i(θ
?
1,θ
?
2)
∂θ2∂θ
T
2
}√n(θˆ2 − θ?2) (5.5)
Following the central limit theorem, we conclude that the joint distribution of statis-
tics − 1√
n
∑n
i=1
∂l1,i(θ
?
1)
∂θ1
and − 1√
n
∑n
i=1
∂l2,i(θ
?
1,θ
?
2)
∂θ2
is normal and given by:
 − 1√n∑ni=1 ∂l1,i(θ
?
1)
∂θ1
− 1√
n
∑n
i=1
∂l2,i(θ
?
1,θ
?
2)
∂θ2
→ N(0,V)
where V =
( V−11 (θ1) R(θ1,θ2)
R(θ1,θ2) V−12 (θ2)
)
, V −11 = E
{(
∂l1
∂θ1
)(
∂l1
∂θT1
)}
, V −12 = E
{(
∂l2
∂θ2
)(
∂l2
∂θT2
)}
,
and R = E
{(
∂l2
∂θ2
)(
∂l1
∂θT1
)}
.
Furthermore, by the law of large number theorem, the asymptotic equivalence of
(5.4) can be written as the following:
√
n(θˆ1 − θ?1) ≈ V1(θ1)
1√
n
n∑
i=1
∂l1,i(θ
?
1)
∂θ1
(5.6)
Plugging (5.6) into (5.5) and applying the law of large number theorem again, we
have:
√
n(θˆ2 − θ?2) ≈ V2(θ2)C(θ1,θ2)V1(θ1)
1√
n
n∑
i=1
∂l1,i(θ
?
1)
∂θ1
+ V2(θ2)
1√
n
n∑
i=1
∂l2,i(θ
?
1,θ
?
2)
∂θ2
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where C = E
{(
∂l2
∂θ2
)(
∂l2
∂θT1
)}
.
By the joint distribution of − 1√
n
∑n
i=1
∂l1,i(θ
?
1)
∂θ1
& − 1√
n
∑n
i=1
∂l2,i(θ
?
1,θ
?
2)
∂θ2
, we obtain
the asymptotic distribution of θˆ2:
√
n(θˆ2 − θ?2)→ N(0,Σ)
where Σ = V2+V2[CV1C
T−RV1CT−CV1RT ]V2 and conclusions follow immediately.
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APPENDIX III: SAMPLING UNDER SNP DENSITY
Since the density under SNP representation is not standard, the sampling from SNP
density, fK(z;ψ), is not straightforward and cannot be called within the existing statis-
tical software packages. Below we provide detailed sampling procedures to sample from
SNP density for K ≤ 2, and more details can be found in Gallant and Tauchen (1992).
Obviously, for the case of K = 0, the distribution reduces to a normal distribution
and thus can be easily sampled. For K > 0 we need to use rejection sampling proce-
dure which requires an envelope (say dK(z;ψ)) that is easy to sample and dominates
fK(z;ψ).
SNP sampling (K=1): For K = 1, we have the density function as the following:
f1(z;ψ) = (a+ zb)
2φ(z) ≤ (|a|+ |zb|)2φ(z)
where a = cos(ψ), b = sin(ψ) and φ(z) is the standard normal density. Therefore, we
construct the envelope as d1(z;ψ) = a
2φ(z) + b2z2φ(z) + 2|ab||z|φ(z). Before moving
on to obtain the samples from density of d1(z;ψ), we establish a useful equation that
connects the density of random variable Z, i.e. fZ(z) and that of the random variable
U = Z2, i.e. fU(u), given as the following:
fU(u) =
1
2
u−
1
2 [fZ(
√
u) + fZ(−
√
u)]
If fZ(z) is a symmetric function, the above equation can be further simplified as
fU(u) = u
− 1
2fZ(
√
u)
Therefore, if random variable Z follows f(z) = c|z|φ(z), then U = Z2 ∼ fU(u) =
c√
2pi
e−
u
2 . However, 1
2
e−
u
2 is recognized as a χ22 density. Thus, random variable Z ∼
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f(z) =
√
2pi
2
|z|φ(z) follows χ2 distribution. Following similar derivations, we conclude
that Z ∼ f(z) = z2φ(z) follows a χ3 distribution. It is evident that φ(z) is a χ1
density. Therefore, we conclude d1(z;ψ) = a
2φ(z)+b2z2φ(z)+2|ab||z|φ(z) is a weighted
mixture of χ density with weight a
2
w
from χ1,
b2
w
from χ3 and
4|ab|
w
√
2pi
from χ2 where
w = a2 + b2 + 4|ab|√
2pi
. A χ distribution can be sampled from χ2 distribution with 50%
chance to be positive and negative, respectively. In summary, the procedures to draw
samples from f1(z;ψ) density are:
Step 1: Draw samples from density d1(z;ψ) = a
2φ(z) + b2z2φ(z) + 2|ab||z|φ(z) which
is a weighted mixture of χ density with weights given above.
Step 2: Use rejection sampling to determine to accept or reject the sample obtained
from Step 1.
Step 3: If sample is accepted, then the sample is from f1(z;ψ). Otherwise, start from
Step 1 again. Repeat these procedures till the desired number of samples are drawn.
The envelope is composed of three parts and each follows a χ distribution. To see
this clearly, Let f(z) = c|z|φ(z) be the density of random variable Z. Furthermore,
let U = Z2 then the density of U , i.e. fU(u), and Z, i.e. fZ(z), is given by fU(u) =
1
2
u−
1
2 [fZ(
√
u) + fZ(−
√
u)]. If fZ(z) is symmetric, then it can be simplified as fU(u) =
u−
1
2fZ(
√
u). Therefore, if Z ∼ f(z) = c|z|φ(z), then U = Z2 ∼ fU(u) = c√2pie−
u
2
where 1
2
e−
u
2 is recognized as a χ22 density and this leads to c =
√
2pi
2
. That is random
variable Z ∼ f(z) =
√
2pi
2
|z|φ(z) follows χ2 distribution which can be sampled from χ22
and taking square root with probability of 0.5 being positive and negative due to the
symmetry about 0. Similarly, for random variable Z ∼ f(z) = cz2φ(z), then U = Z2 ∼
fU(u) =
c√
2pi
u
1
2 e−
u
2 and 1√
2pi
u
1
2 e−
u
2 is a χ23 density. Thus, Z ∼ f(z) = z2φ(z) follows a χ3
distribution which can be drawn from a χ23 and taking square root with probability 0.5
being positive and negative due to symmetric about 0. Therefore, d1(z;ψ) is a weighted
χ mixture with weight a
2
w
from χ1,
b2
w
from χ3 and
4|ab|
w
√
2pi
from χ2 where w = a
2+b2+ 4|ab|√
2pi
.
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SNP sampling (K=2): For K = 2, we have the following:
f2(z;ψ) = (a+ zb+ z
2c)2φ(z) ≤ (|a|+ |zb|+ z2|c|)2φ(z)
where a = cos(ψ1) − sin(ψ1)sin(ψ2)√2 , b = sin(ψ1)cos(ψ2) and c =
sin(ψ1)sin(ψ2)√
2
. Therefore,
we construct the envelope as:
d2(z;ψ) = a
2φ(z) + 2|ab||z|φ(z) + (b2 + |2ac|)z2φ(z) + |2bc||z3|φ(z) + c2z4φ(z)
Following similar tedious derivations as above, we conclude d2(z;ψ) is also a mixture
of χ density with weight a
2
w
of χ1,
4|ab|
w
√
2pi
being χ2,
b2+|2ac|
w
from χ3,
8|bc|
w
√
2pi
being χ4 and
weight 3c
2
w
from χ5 with w = a
2 + 4|ab|√
2pi
+ b2 + |2ac| + 8|bc|√
2pi
+ 3c2. Therefore, similar
procedures as above can be used to draw samples from density f2(z;ψ).
To see this clearly, we let f(z) = c|z3|φ(z) be the density of random variable Z and
U = Z2. Thus, fU(u) = u
− 1
2 [ c√
2pi
u
3
2 e−
u
2 ] and u
4
e−
u
2 is the density of χ24. Thus, Z ∼
√
2pi
4
|z3|φ(z) can be sampled from χ4 distribution by taking the square root of a random
sample from χ24 distribution with the probability of 0.5 being positive and negative,
respectively. Similarly, Z ∼ f(z) = cz4φ(z) and U = Z2 lead to fU(u) = c√2piu
3
2 e−
u
2 .
If c = 1
3
, then fU(u) is the χ
2
5 density and we conclude that Z ∼ f(z) = 13z4φ(z)
can be drawn from χ25 distribution and take square root with 0.5 probability being
positive and negative. Therefore, d2(z;ψ) is a weighted χ density with weight
a2
w
of
χ1,
4|ab|
w
√
2pi
being χ2,
b2+|2ac|
w
from χ3,
8|bc|
w
√
2pi
being χ4 and weight
3c2
w
from χ5 with w =
a2 + 4|ab|√
2pi
+ b2 + |2ac|+ 8|bc|√
2pi
+ 3c2.
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